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RÉSUMÉ
Introduction: La persistance et l’adhésion aux traitements de l’asthme combinant les
corticosteroïdes inhalés (CSI) et les béta2-agonistes à longue action (BALA) dans le
même inhalateur (traitement de combinaisons) comparativement aux thérapies
concommitantes avec les deux médicaments inhalés séparément (traitement
concommittant) sont peu documentées.
Objectif: Comparer la persistance et l’adhésion entre les patients asthmatiques âgés
entre 16 et 44 ans débutant un traitement combiné de BALA et de CSI et ceux débutant
une thérapie concommitante des deux médicaments.
Méthode: Étude rétrospective de cohorte appariée, reconstruite à partir des banques
de données de la Régie de l’assurance-maladie du Québec en sélectionnant des
patients débutant l’une des deux thérapies entre janvier 1999 et décembre 2002. Les
patients sous combinaisons ont été appariés un à un aux patients sous traitement
concommitant en fonction de marqueurs de contrôle et de sévérité de l’asthme dans
l’année précédant le début du traitement. La persistance est déterminée par des
analyses Kaplan-Meier et par un modèle de régression de Cox ajusté (variables socio
démographiques et marqueurs de sévérité et de contrôle) alors que l’adhésion est
évaluée chez les patients persistants selon le pourcentage de jours sous traitement en
relation avec la quantité de médicament dispensée, en comparant les deux traitements
à l’aide d’un modèle de régression linéaire.
Résultats: La persistance diminue à 10% et 5% 12 mois après l’initiation du traitement,
puis à 5% et 2% sur une période de 24 mois chez les utilisateurs de produits de
combinaisons et de traitement concommitant, respectivement. Les utilisateurs d’une
thérapie combinée ont 17% moins de chance de cesser leur traitement (taux relatif:
0,83; 95%Cl: 0,78-0,88) et comptent en moyenne 0,9 plus de prescriptions renouvelées
par année que les utilisateurs d’une thérapie concommitante (pO,000l). Les
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utilisateurs de thérapie concommitante cessaient leur traitement au BALA sensiblement
plus que les CSI (p <0,0001). Le nombre de jours sous traitement pendant la première
année était significativement supérieur chez les utilisateurs d’une thérapie combinée
(90,4 vs. 73,1; p<0,0001). L’adhésion au traitement était sensiblement inférieure chez
les patients sous thérapie combinée comparativement à celle des patients sous thérapie
concommittante (55% vs. 58%; p=0,003l).
Conclusion: Les patients sous thérapie combinée étaient sensiblement plus
persistants que les utilisateurs de thérapie concommittante, mais relativement moins
adhérants. La persistance aux traitements inhalés de maintenance est très faible chez
les patients asthmatiques d’âge adulte.
Mots clés Asthme, corticostéroïdes inhalés, béta2-agonistes à longue durée d’action,
base de données administratives, pharmaco-épidémiologie, produits de combinaison,
cohorte.
VABSTRACT
Background: Limited evidence exists on persistence and adherence with asthma
combination regimens including both inhaled corticosteroids (ICS) and long-acting f32-
agonists (LABA) within the same inhaler (combinations) compared to these medications
inhaled separately (concurrents).
Objective: To compare persistence and adherence between 16-44 years old asthmatic
patients, starting a single-inhaler combination of ICS and LABA or a concurrent regimen
of both medications.
Methodology: This retrospective one-to-one matched cohort is based upon daims
data. Newly treated asthmatics with either a combination or concurrent therapy were
selected from the Régie de l’assurance maladie du Québec (RAMQ) database between
]anuary 1999 and December 2002. Combinations were one-to-one matched to
concurrents using markers of asthma severity and control in the year prior to treatment
initiation. Persistence was determined by a Kaplan-Meier analysis and a Cox
Regression model, adjusting for socio-demographics and markers of asthma severity
and control. Adherence was estimated according to the number 0f filled prescriptions in
relation to the time patients persisted on the prescribed therapy and compared between
the two drug regimens using a linear regression model.
Resuits: Persistence feU to 10% and 5% 12 months after treatment initiation, and to 5%
and below 2% over 24 months for combination and concurrent users, respectively.
Overall, combination users were found to be 17% less likely to stop their treatment
(adjusted hazard ratio 0.83; 95%Cl: 0.78-0.88) and filled on average 0.9 more
prescription per year than concurrent users (p-value0.0001). Concurrent users ceased
their LABA treatment stightly more than ICS (p-value <0.0001). Average days under
treatment during the first year was significantly higher with combinations (90.4 vs. 73.1;
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p<O.0001). Treatment adherence was slightly Iower for patients taking combinations vs.
concurrents (55% vs. 58%; p=O.003l).
Conclusion: Combination users were slightly more persistent than concurrent therapy
users, but reativeIy Iess adherent. Persistence to inhaled controller therapies is very Iow
among aduit asthmatic patients.
Key words Asthma, inhaled corticosteroids, long-acting beta2-agonists, administrative
database, pharmacoepidemiology, combination, cohort.
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INTRODUCTION
The international guidelines (GINA)1 and latest Canadian consensus2 uphold the
concept of asthma management as a continuum, contingent on underlying symptoms
severity and pulmonary tests resuits. When asthma is not optimally controlled with
inhaled corticosteroids (ICS) alone, the addition of long-acting 32-agonists (LABA) to
ICS is accepted as the most effective therapy to control moderate to severe asthma.3
This therapeutic approach is also supported by NAEPP guidelines4 for the treatment of
uncontrolled persistent asthma. ICS and LABA have a complementary effect,5’6’7’8
treating both components of asthma: underlying airway inflammation and obstruction,
respectively 3,9,10• It has been shown that this regimen provides greater asthma control
than increasing the dose of ICS 11,12 and may also improve outcomes (lung function,
exacerbation rates, and quality of life) in asthmatics who remain symptomatic on ICS.13
The administration of both ICS and LABA concurrently with different inhalers or
using a single inhaler combining both medications may not be equivalent. Concurrent’
administration entails the manipulation of two different inhaling devices (one for each
drug) whereas combination’ involves a single inhaling device which contains both
agents.14 Two combination products are presently available in Canada: one combining
fluticasone (ICS) and salmeterol (LABA) into the same inhaler, known as
Advair/Seretide, and another combining budesonide (ICS) and formoterol (LABA) into
the same inhaler, known as Symbicort.
Average medication compliance, an essential component of a successful health
outcome, has been shown to be lower in patients with respiratory disorders, most of
which require inhaled medications.15 Although inhaled corticosteroids are the most
effective treatment for asthma, historically they have elicited poor compliance, likely
because patients may flot perceive the medication to be working.15 lt has been shown
that adherence to asthma treatments declines as the regime becomes more
2complicated, either by increasing the number of medications and/or the number of daily
doses.16’17
Systematic reviews of compliance literature18’19 have shown that simplet, less
ftequent dosing regimens resulted in better compliance across a variety cf therapeutic
classes. Intuitively, a combination regimen of corticosteroid/beta2-agonist in one inhaler
is likely to improve patient compliance by simplifying the treatment tegimen and
providing noticeable symptom relief while alleviating the underlying inflammation.
Consequently, it has been hypothesized20’21 that the use cf combination inhalers can
improve patient’s adhetence and consequently overail asthma control.22’23’24 However,
limited evidence exists on persistence and adherence with asthma combination tegimen
including bath ICS and LABA within the same inhaler compared to these medications
inhafed separately. Sa far, we found two published studies25’26 in which this hypothesis
was tested in usual care clinical practice settings in the US. We thus performed a
population-based cohort study to compare treatment persistence and adherence
between 16-44 years old asthmatic patients starting a combination and a concurrent
therapy, using data collected in the Régie de l’assurance maladie du Québec database.
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OBJECTIVES
The objectives of this study were the following:
1. To estimate treatment persistence and adherence with combination therapy
(LABA plus ICS in one device) among asthmatic patients aged between 16-44
years old;
2. To estimate treatment persistence and adherence with LABA prescribed
concurrently with ICS (in two devices) among asthmatic patients aged between
16-44 years old;
3. To compare treatment persistence and adherence between the two drug
reg imens.
This study was conducted to provide significant real-life information for asthma patients
and their treating physicians on the hypothesized adherence and persistence benefits
that would be expected from the ease of administration of combination therapy
reg i mens.
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LITERATURE REVIEW
Asthma definitïon
Inflammation and its resultant effects on airway structure are considered to be
the main mechanisms leading to the development and maintenance of asthma.27 In the
recent Global Initiative for Asthma (GINA) Guidelines1, asthma is defined as a chronic
inflammatory disorder of the airways in which many cells and cellular elements play a
role. The chronic inflammation causes an associated increase in airway
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness,
chest tightness, and coughing, particularly ai night or in the early morning. These
episodes are usually associated with widespread but variable airflow obstruction that is
often reversible either spontaneously or with treatment.1
Burden of Asthma
Despite advances in understanding the disease and the availability of more
effective treatments, asthma still places a heavy burden on the quality of life of those
suffering from it. This is often a resuit of under-diagnosis, under-treatment, lack of
understanding and knowledge about the disease, and inadequate asthma supervision.28
Asthma Worldwide
Worldwide, the rate 0f asthma is increasing significantly, rising by 50 percent
every decade.29 Currently, approximately 300 million people (or about 5% of the global
population) suifer from asthma and this figure is expected to increase by an additional
100 million people by 2025.29 It is estimated that asthma accounts for about one in
every 250 deaths worldwide.29
Asthma in the US
A 1998 document from the United States Department of Health and Human
Services reported a sharp increase in the rate of self-reported asthma among ail age
groups between the years 1980 and 1994, from 30.7 to 53.8 per 1,000(3.1% to 5•4%
)•30
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In 2003 t was estjmated that 20 million Americans had asthma. 0f these, 11 million
Americans had an asthma attack and it is estimated that about 30 million Americans or
about 10 percent of the U.S. population, have been diagnosed with asthma in their
lifetime, according to the American Lung Association and the National Center for Health
Statistics.4 In the United States alone, asthma was estimated to result in 10 million
missed school days, over 1.5 million emergency department visits, approximately
500,000 hospitalizations, and over 5,000 death annually.31’3233’34
Asthma in Canada
In Canada, the number of people with asthma has been incteasing over the Iast
15 years.35 Currently, Canada has one of the highest incidences 0f asthma in the world,
with an estimated 2.2 million Canadians (8.4 per cent of the population) over the age of
12 currently diagnosed with asthma.36 As of March 2005, an estimated five per cent of
adults have taken medications for asthma or have experienced symptoms in the past 12
months.37 According to the 1996-1997 National Population Health Survey (NPHS)
Asthma Supplement, 35% 0f individuals with current asthma have been restricted in
their daily activities by asthma; 22% for one to five days and 13% for more than five
days in the previous year. The number of hospitalizations due to asthma may be a
more serious sign of poor disease control; 5.3% of those diagnosed with asthma in
Canada require hospitalization each year.38 In Canada, direct costs of asthma, which
include medical/nursing care and medication, are estimated at $600 million per year39.
In 1994, the cost of hospitalization as a result of asthma was $135 million in Canada.37
Visits to emergency rooms may also be a sign of poorly controlled asthma. The NPHS
Asthma Supplement survey found that 18% of individuals with active asthma had visited
an emergency department at Ieast once in the previous 12 months.38 With 146,000
emergency room visits every year due to asthma attacks40, asthma is the leading cause
of emergency room visits29 and the third leading cause of work Ioss in Canada.41
6Asthma mortality rates in Canada increased from 1970 to the mid-1980s; however by
1995 they had decreased to below the 1970 level, except in young aduits where
increases had been more important in the 1970s.35 While the death rate from asthma
has slowly decreased since 1990, there are stiil approximately 10 asthma deaths per
week in Canada; asthma is the cause of deaths cf 20 children and 500 adults each
year.4° It is estimated that more than 80 per cent of deaths due to asthma could be
prevented with proper education.41
Asthma disease management and treatment goal
It has been shown that an underassessment cf asthma severity resuits in
ineffective treatment and suboptimal outcomes.4243 In Canada, clinical practice
guidelines te diagnose and establish treatment plans for patients with asthma are
provided by the Canadian Asthma Consensus Guidelines27. According to the Canadian
Consensus, the primary goal cf asthma therapy is to obtain the best possible resuits for
each patient, which include: fewest symptoms, least interference with daily living, least
need for “rescue medications” and best lung function test 0f forced expiratory volume
(FEV) or peak expiratory flow, and fewest side effects from medications. Overall, the
therapy should lead to adequate control of the disease in order to reduce the
consequences of asthma and, ideally, its severity over time.27’32 However, a conceptual
concern about the different approaches to asthma severity categorization is that these
methods are based on the concept cf asthma control rather than asthma severity.44 We
need to distinguish underlying severity from current control severity.
Canadian Consensus
The overail approach advocated by the Canadian Consensus27 for the management cf
asthma clearly distinguishes asthma control and asthma severity assessments. Asthma
severity is more difficult to assess and may only be determined after asthma control is
achieved.2
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Optimal control of asthma is characterized by the absence of respiratory
symptoms and of the need for rescue bronchodilator, as well as normal pulmonary
function27. This is difficult to achieve in ail patients with asthma, so treatment needs are
based on acceptable’ asthma control, defined using clinicai and physiologic parameters
(Table 2 — page 81)27. Optimal management of asthma requires adequate evaluation of
the patient and his or her environment; a clinician should also evaluate new patients’
asthma using the asthma control criteria (Table 2).2 Asthma control may be achieved
through apprapriate environmental measures, adequate patient education and
pharmacatherapy tailared ta the individual. Once contrai of asthma has been
maintained for at ieast several months, an attempt should be made ta reduce
medicatian within the baunds of acceptable contrai27.
The severity of asthma in a patient is judged by the frequency and duration of
respiratory symptams, the presence of persistent airfiow limitation and the medicatian
required ta maintain contrai.27 Signs of severe or pooriy controlled asthma combine
features of: lung functions (forced expiratory volume in one second (FEV1) or peak
expiratory flow (PEF) below 60% of predicted values); symptoms contrai (limitation of
daily activities, night-time symptoms; need for an inhaied 32-agonist several times a day
or at night); histary af hospital admissions or emergency department visit(s); and the
occurrence cf a prior near-fatal episode (loss of consciousness, need for intubations). 27
The iatest issue of the Canadian guidelines2 uphold the concept of asthma
management based on a stepwise continuum (Figure 1 — page 84), commensurate with
underlying symptoms and puimonary function tests resuits, ta determine the appropriate
therapeutic regimen which are listed in Table 3 on page 81. If contrai is inadequate, the
reason(s) should be identified and maintenance therapy modified according ta the
continuum2 (Figure 1). When asthma is well controlled, one of the best ways to judge
severity s to determine the level cf treatment needed to maintain acceptable control.27
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Moreover, since asthma severity is likely to vary over time,27 any new treatment should
be considered a therapeutic trial and its effectiveness should be re-evaluated after 4—6
weeks according to the asthma management continuum.2
In a recent 3-year observational database study of asthmatic patients, Stempel
et aL45 documented that asthma control - on the basis of medical and pharmacy daims -
might change over time, itrespective of age, sex, and prior asthma control status. That
study emphasized the need to address asthma control both in patients with initially weII
controlled disease and in those patients who present with evidence of uncontrolled
asthma since both groups continue to be at risk for asthma symptoms as well as for
asthma exacerbations. This finding is of particular relevance to highlight the value of
using database to monitor asthma control variations from the pre-initiation period, at
index date, as well as throughout the analysis of prescribing trends and medication refill
rates used as a proxy for drug utilization over time.
Other Asthma Guidelines
The asthma severity and control assessments proposed by the Canadian
Consensus27 combine features that are also supported by other widely known
guidelines. For instance, the American guidelines (NAEPP Expert Panel Report 2)32
also recommend an assessment of asthma based on symptoms (diurnal and nocturnal)
as well as lung function prior to the initiation of a treatment. Within each of these three
variables, levels of gradation in severity established by the NAEPP lead the physician to
classify a patients asthma into one of four separate categories, and overall asthma
severity is then determined according to the worst individual variable. The British
Guidelines on the Management of Asthma46, also recommend an individual assessment
of severity based on diurnal and nocturnal symptoms, and include physical activity
limits, exacerbations, absence from school or work, use of rescue SABA, and lung
function. The National Asthma Campaign in Australia47 stipulates that asthma severity
9should be assessed while the patient is clinically stable, and that severity categorization
would rest on a history cf either hospitalization or near-fatal asthma attacks. The
inclusion cf historical features differs from the NAEPP approach to severity
categorization in that aspect; the US recommendations concenttate on current
symptoms and lung function abnormalities. As shown in Table 4 on page 82, the
Canadian Consensus guidelines2 combine aspects from both the British and the
Australian methods: five disease severity categories like the British Guidelines, and
three separate categories cf control based on symptoms as defined above, similar to the
Australian guidelines.
Asthma treatments
There are several types cf current therapies in asthma, which could mainly be
grouped as either bronchodilators or anti-inflammatory therapies (Table 3 — page 81),
also referred te as relievers or controllers respectively. Bronchodilators relax airway
smooth muscles and provide immediate relief from asthma symptoms such as wheezing
and shortness cf breath, whereas anti-inflammatory therapies are used as a
maintenance treatment cf the underlying inflammation which characterizes asthma. The
bronchodilators ccnsist cf inhated short-acting 32-agonists (SABA), inhaled long-acting
Ç32-agonists (LABA), inhaled anticholinergics, and thecphyline. In the Canadian
Consensus2, anti-inflammatory therapies include inhaled corticosteroids (ICS),
antileukotrienes and cromones.
Recommendation ICS first-Iine
‘Reliever’ medications such as SABAs provide rapid relief cf acute
bronchoconstriction and it has been shown that patients tend te take mcre as-needed
medication as their asthma control declines.48 Based upon the recognition that asthma
is primarily an inflammatory condition, the Canadian Consensus27 advises that the major
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thrust of therapy should be controlled using anti-inflammatory therapy. lnhaled beta2-
agonists may therefote only be used infrequently; SABAs are only recommended for
use as-needed.
It has been well established that inhaled corticosteroids (ICS) relieve persistent
symptoms very effectively, improve lung function, decrease bronchial
hyperresponsiveness and reduce morbidity caused by asthma.495051’525354 Several
randomized clinical trials in adults with asthma concurred that ICS might be the most
effective available medication in improving forced expiratory volume in one second
(FEV1).55’56 Observational study resuits showed that regular use of low dose ICS could
reduce asthma hospitalizations by as much as 80%, both early and later on in the
course of the disease.54’5758 In addition, it had previously been shown that compliance
with ICS therapy reduces the risk 0f asthma exacerbations as well as the risk of death
from asthma by 21% for each additional ICS canister used.59 Not surprisingly, ICS
constitute the preferred controller medication in the treatment of persistent asthma
because they are the most effective with the least side effects anti-inflammatory
medications available for treating the underlying inflammation.260 This is reflected in
current practice, where the use of controller medication increased 8-fold between 1978
and 2002, inhaled corticosteroids (ICS) manifesting the biggest increase.61
Therefore, on the basis of substantive Level 1 evidence - defined as randomized
controlled trials (RCTs) or meta-analysis 0f RCTs of adequate size to ensure a low risk
of incorporating false-positive or false-negative results2 - several guidelines, including
the Canadian Consensus, recommend ICS as first-line agents in the tteatment of
patients with persistent asthma.462 Studies have shown that the early initiation of anti
inflammatory therapy (i.e. within 2 years of the onset cf symptoms) with ICS is believed
to improve the prospects of achieving good long-term asthma control63’64’65. In addition,
11
there is evidence ta suggest that this approach may reduce airway remodeiling66. In
previous reports, the Canadian Consensus positioned ICS as the mainstay of asthma
therapy and as ciearly indicated in ail but the mildest cases.27 The iatest update of the
Consensus recommend ICS as the optimal intervention even for patients with mild
persistent asthma.2 Inhaled corticosteroids tICS) should therefore be introduced as the
initial maintenance treatment for asthma, even in subjects who report asthma symptoms
less than three times per week.2 Daiiy iong-term contrai with ICS is therefore
recommended ta prevent exacerbations and chronic symptoms for ail patients with
persistent asthma, whether the persistent asthma is miid, moderate, or severe.
Recommendations ICSILABA
However, when a patient’s asthma is flot well controlled with first-line inhaied
corticosteroids therapy alone, the use of both ICS and Iong-acting Ç3-agonist (LABA)
therapy is accepted as the most effective treatment regimen ta contrai moderate and
severe asthma.3 As part 0f their stepwise approach for asthma management, both
International (GINA)1 and Canadian guidelines22762 recommend the use of iow dose ICS
coupled with inhaled LABA, based on the physician’s assessment of the patient’s
underlying severity 0f asthma symptoms. This therapeutic approach is also supported
by NAEPP4 guidelines as the most convenient and effective regimen for uncontroiled
persistent asthma.
ICSILABA - Improved Outcomes
ICS and LABA have a compiementary effect,56’7’8 treating both components of
asthma: underlying airway inflammation and airway obstruction, respectiveiy.3’91° In an
eariier landmark triai, Greening et al. demonstrated that treatment with both ICS and
LABA provides greater asthma control for patients not optimally controiied on a
moderate-dose iCSJ It has aiso been shown that the maximal effect of this regimen
could be obtained when the added LABA (salmeterol) dose was 5Oug twice daiiy.67 The
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lesser effect of higher dose ICS on lung function is likely to be a reflection of the
plateauing dose-response curve of ICS, particularly when responses such as PEFR,
FEV1, and bronchial responsiveness are measured.68’69
ICS/LABA vs. Increased dose of ICS
In an extensive metaanalysis including several clinical trials, the addition of
LABA to tow-dose fluticasone was superior to increasing the dose of fluticasone in
patients with moderate to severe persistent asthma.’2 This regimen lead to
improvements in spirometry, and in symptoms score as well as to a decreased number
of exacerbations.7° Other trials involving the ICS/LABA combination also confirmed that
LABA plus low-dose ICS (88ug twice daily) was more effective than higher-dose ICS
alone in reducing asthma exacerbations in patients with persistent asthma,71 in
improving morning peak expiratory flow, and in leading to a 26% decrease in symptom
free days72. The Gaining Optimal Asthma ControL (GOAL) study has also shown the
superiority of a combination cf salmeterol/fluticasone propionate (SEC) compared with
fluticasone propionate alone (EP) in terms cf improving guideline-defined asthma
control.73
The FACET trial showed reduction in asthma exacerbations and increase in
morning PEF with the addition of formoterol irrespective of the budesonide dose. The
addition of formoterol to low dose budesonide was more effective than a fourfold higher
dose of budesonide alone.74 Similar conclusions could also be reached according to the
results of the OPTIMA trial75. In that study, a first group of 698 patients was randomly
assigned to receive a 10w dose lCS (100 pg budesonide twice daily) and a LABA (6 pg
formoterol twice daily), an ICS alone (100 pg budesonide twice daily) or placebo. The
addition of 6 pg of formoterol to the ICS resulted in improved lung function. However,
no additional benefit was found with this combined regimen when compared with
budesonide alone (100 pg twice daily) in that mild asthma patients group. Compared
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with placebo, even in patients with mild asthma, the addition of an ICS resulted in a 68%
reduction in severe exacerbations, In the second OPTIMA study group (n = 1272)
composed of patients previousfy been treated with ICS and having slightly wotse lung
function (mean FEV1 predicted value 86% compared with 90%), the addition of
formoterol did provide additional benefit compared with placebo and, more importantly,
compared with doubling of the dose of the ICS.
Overall, there does not appear to be any difference between the use of ICS
alone or in combination for patients with mild asthma who have neyer received an ICS,
while it is clear that the combined ICS/LABA regimen provides benefits for patients with
moderate to severe asthma. The Canadian Consensus27 reviewed other available
data76 and concluded that there is insufficient evidence of additional benefit for the initial
use cf combination inhaler therapy in patients with mild persistent asthma who have flot
been treated previously with ICS.
ICSILABA — Synergy
In summary, clinical trials evaluating the effect cf adding LABA therapy te ‘low
dose’ ICS demonstrated improvements in asthma outcomes in terms cf both lung
function and exacerbation rates, in asthmatic patients who remain symptomatic on low
dose ICS alone. Moreover, it has been shown that LABA added te ICS therapy provides
superior asthma control compared with the addition of teukotriene modifiers7776 or
theophylline.79 Earlier findings concluded that the superior control cbtained with the
LABNICS combination is likely a consequence cf the complementary actions cf the
drugs when taken together, potentially the activation cf the glucocorticoid receptor by
salmeterol.8° Myo et al. have recently dccumented that a synergistic/additive effect cf
the ICS/LABA combination might be on molecular pathways that are flot typically
considered stercid sensitive, i.e. the cascade cf inflammatcry mediators deriving frcm
membrane phosphclipid metabclism.5 Another recent publication assessing the synergy
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of LABNICS regimens stated that molecular interactions between corticosteroids and
beta2-adrenoceptors may underlie the clinical added benefits of combination therapy81.
The combination of corticosteroids and LABA potentiates inhibition of interleukin-8 and
eotaxin release from human airway smooth muscle ceils and granulocyte-macrophage
colony-stimulating factor release from epithelial cells, and also the inhibition of airway
smooth muscle celI proliferation.81
Concurrent vs. Combination
The use of LABA plus ICS in a concurrent (or concomitant) use versus a
combination technique may flot be equivalent. ‘Concurrent’ entails the manipulation of
two different breath-activated devices (one for each drug) and ‘combination’ denotes a
single inhaling device which contains both agents. Therefore, combination therapy
implies only one inhalation maneuver per dose, whereas concurrent therapy implies
two.14 There are two commercial products that combine a LABA (formoterol or
salmeterol) and an ICS (budesonide or fluticasone). These two combination products
are presently available in Canada: (1) GlaxoSmithKline markets Advair® as 100/50
micrograms, 250/50 micrograms or 500/50 micrograms dry powder inhalers of
fluticasone propionate (ICS) / salmeterol xinafoate (LABA) into the same inhaler
(Diskus®), with each inhalation providing 50 pg of salmeterol and 125/25 and 250/25
fluticasone/salmeterol in metered dose inhalers. The unit cost for these products varies
from $77.80 to $132.16, depending on the strength. The supply is expected to last for
an average of one month. (2) AstraZeneca markets Symbicortc as 100/6 micrograms
or 200/6 micrograms of budesonide/formoterol dry powder inhaler (Turbuhaler®). Unit
costs for these products are $65.10 and $84.63 respectively. The supply is expected to
last for an average of one or two months.82
C
Improved Safety with combined inhalers
Short-acting 32-agonists have been used for symptom relief for many years.83
However, it has been shown that SABAs are overused and that this inappropriate use,
particularly among ICS users, might be explained by undertreatment or poor compliance
with ICS.84 Inhaled beta-agonists may be associated with excessive and inappropriate
reliance on symptomatic treatment in poorly controlled asthma.85 The inappropriate use
of LABA as monotherapy without ICS also raises safety concerns and this practice does
flot hold with international guidelines1’ nor with the Canadian Consensus
recommendations.27 Combination inhalers ensure that patients cannot neglect their ICS
maintenance therapy in fayot of the LABA,82 because patients may petceive the benefits
of bronchodilation more easily, which may improve adherence and overall asthma
control.22 Recently, a long- but also fast-acting agent, formoterol, has been approved
for symptom relief.86 It is important to reiterate that based on current evidence fast
acting bronchodilators may be used to telieve acute intermittent asthma symptoms, but
only on demand and at the minimum dose and frequency required. When a reliever is
needed for more than 3 times a week (aside from a pre-exercise dose), it suggests
suboptimal asthma control and indicates the need to re-assess treatment.
87
Safety Issues with LABA Monotherapy
Several studies have shown the detrimental effect of using LABA as
monotherapy. In a randomized, double-blind, placebo-controlled, parallel-group study
with salmeterol, Lazarus and al.88 showed that despite reasonable control of symptoms
and lung function, treatment failure and asthma exacerbations occurred more often in
the salmeterol-treated group (42 pg twice daily) compared to patients treated with
triamcinolone (400 pg twice daily). Another study evaluating the corticosteroid-sparing
effect of LABA noted a large increase in asthma exacerbations (46.3% of patients) after
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complete elimination of triamcinolone compared with subjects taking both trimaciolone
(400 pg twice daily) and salmeterol (13.7% 0f patients)89 Furthermore, this has recently
been conflrmed with the interim analysis 0f the recently discontinued SMART study,
which demonstrated that salmeterol was associated with a significantly higher
prevalence of adverse events, including death, than a placebo in the approximately 50%
of 26,000 subjects who were flot on ICS.9° Although effective when given with an ICS, it
has been suggested that a reduced effect over time and receptor desensitization, flot at
the bronchial smooth muscle level but on the mast ceils and lymphocytes, may account
for the relative lack of evidence of an effect of the LABAs on airway inflammation.85 By
combining anti-inflammatory treatment with a LABA in a single inhaler, both the
inflammatory and bronchoconstrictive aspects of asthma can be covered without
introducing any new or unexpected adverse consequences. The most common drug
related adverse events with the LABNICS combination were those known to be
attributable to the constituent medications (ICS therapy and/or LABA therapy).9
Better outcomes with Combined Inhalers vs. Low Dose ICS
The benefits of combination therapy include better day-to-day control and a
reduction in exacerbations compared with monotherapy with ICS at a lower dose.23
Total control of asthma - defined as no daytime or night-time symptoms, no use of
rescue SABAs, no exacerbations and a peak flow rate of >80% predicted - may be
achieved with the use of combined salmeterol/fluticasone in a single inhaler in up to
41% of patients with moderate to severe asthma, compared with only 28% of patients
treated with fluticasone alone. Superior asthma control and improved patient quality of
life were subsequently demonstrated in favor of the combination therapy in studies
comparing the budesonide/formoterol combination with budesonide alone.9192
Furthermore, there is evidence suggesting that ICS and LABA administered in a single
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inhaler may be superior in reducing asthma exacerbations than the administration of the
same products in two separate inhalers.93
Combinatïon fluticasone!salmeterol
The first trial comparing the combination and concurrent use of
fluticasone/salmeterol conducted by Aubier et al.94 showed that both combination and
concurrent therapies achieved significantly greater improvement in morning and evening
PEFR compared to fluticasone alone. Both combination and concurrent therapies
improved PEFR by 10% whereas fluticasone alone improved morning PEFR by 4%.
Further studies also demonstrated that combination treatment with both LABA and ICS
in the same inhaler was as effective as using two separate inhalers to deliver LABA and
ICS.9596’979899 The EDICT trial by Ringdal et al. showed that in symptomatic patients
with moderate-to-severe asthma, fluticasone/salmeterol (50/250 microg bd),
administered in a single device (Diskus), was at least as effective as an approximately
three-fold higher microgram corticosteroid dose of budesonide (800 microg bd) given
concurrently with formoterol (12 microg bd) in terms of improvement in PEFam, and
superior at reducing exacerbations and nights symptoms or awakenings.
Fluticasone/salmeterol was also the less costly treatment due primarily to lower
hospitalization and drug costs according to that study.16
Combination budesonidelformoterol
The first trial using budesonide/formoterol in a single inhaler was conducted by
Zetterstrom et al.91 In patients with persistent asthma symptoms despite treatment with
ICS, budesonide/formoterol administered via a single dry powder Turbuhaler device
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appears to be as effective as treatment with the constituent medications administered
via separate inhalers in improving PEF, controlling symptoms and preventing mild
exacerbations. Adjustable maintenance dosing with budesonide/formoterol is associated
with a lower overall dosage and appears to maintain control as effectively as fixed
dosing.2410° Another study comparing self-guided adjustable maintenance dosing with
budesonide/formoterol in a single inhaler with fixed dosing showed that asthma patients
on adjustable maintenance dosing with budesonide/formoterol maintained control of
symptoms using significantly less medication overall than fixed dosing. Adjustable
maintenance dosing achieved guideline goals of effective asthma control at an
appropriately low maintenance dose.101
Bronchodilating action
A recent double-blind, placebo-controlled, cross-over study
102 involving twenty
subjects with mild to moderate asthma showed that the bronchodilating action of the
long-acting beta-agonist formoterol administered as a single evening dose from the
combination budesonide/formoterol Turbuhaler (2x1 OOI6mug) attenuated the biphasic
pattern of the circadian rhythm in airway tone, resulting in a bronchodilation of at least
24h. Lung function measurements were assessed at baseline, at 1h and subsequently
every 4h post-dose for 24h. The results of that study showed that compared with
placebo, the combination budesonide/formoterol Turbuhaler significantly improved the
three measures cf airways function (FEV1), specific airways conductance (sGaw) and
maximum expiratory flow at 25-75% of vital capacity (MEF(25-75%))) throughout the
24h period, with a difference in FEV1 at 24h cf O.20L (O.04-O.35L).
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Combination fluticasonelsalmeterol versus Combïnatîon budesonide/formoterol
More recent literature report on findings from head-to-head assessments of both
combination regimens, however the focus was mainly on fixed versus adjustable dosage
which extend beyond the scope of this research study. A recent review103 of the
publications on the clinical evidence of budesonide/formoterol and
salmeterol/fluticasone regimens concluded that both are effective and well-tolerated
asthma treatments.
Reduced complexity
Adherence to medical therapy (the extent to which recommendations are
followed as defined) is a complex and dynamic behavioral process that is strongly
influenced by the patient, his or her support environment, practices of health care
providers, and the characteristics of care delivery systems.104 Moreover, it has been
shown that adherence to treatment in asthma declines as the regime becomes more
complicated, either by increasing the number of medications and/or the number of daily
doses.1617 Therefore, complexity of drug regimen is a well-established contributor to
poor compliance and simplified regimens are associated with better
compliance.’9’105106107’108 As a resuit, more convenient treatments may represent an
important benefit for patients with asthma, and an effort to simplify the complexity of the
therapy could also result in improved adherence, potentially leading to better disease
control.24 For example, resuits of a recent RCT suggest that not only is the combination
of budesonide/formoterol in a single inhaler as safe and effective in the long-term
treatment of asthma as its constituent agents taken concurrently, but also that the lower
number of withdrawals (frequency of discontinuation due to asthma deterioration from
recorded adverse events) with this combination therapy may reflect beller adherence to
treatment compared with both agents taken via separate inhalers.109 With its fast onset
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of action (due to the bronchodilating effect of formoterol), this combination therapy may
help patients feel more in control of their condition and improve adherence to their
medication.24
Effectiveness vs. Efflcacy
The relative effectiveness of combined vs. separate delivery modes in actual clinical
practice may be different. Clinical studies used to support the guidelines are not
indicative of ‘real life’, where patients frequently cannot use their inhaler correctly.11°
Differences in adherence to recommended therapies between real world and clinical
trials may contribute to the differences in results from these two distinct environments.
In clinical trials, patients are carefully selected and supervised for their adherence to
recommended therapies and meticulously trained on the use of their inhalers. In clinical
practice, the most effective treatments require the utilization of inhalers, such as ICS
which are used with inadequate technique by a significant numbers of patients.
,U2,H3
The fact that asthma is a chronic illness involving long-term therapy combined to the
difficulty for patients to adequately manipulate their inhaler may lead to poor
persistence, consequently reducing the effectiveness of asthma therapy in clinical
practice.
Although the benefits of combined ICS plus LABA therapy can be achieved with
separate inhalers, the convenience of combination regimens may improve patient
adherence and may therefore reduce the morbidity of asthma.2481 However, there is
limited evidence demonstrating that improved adherence in current practice resuits from
the use of combination therapy of LABA and ICS instead of the concurrent therapy.
Two retrospective cohort studies measured treatment adherence using the number of
prescriptions recorded in a United States daims database over a 12-month period.
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Stoloif et al. published the first study25testing this hypothesis. Prescription refui rates for
asthma medications were determined for a cohort of 2511 patients aged 12 years or
older who had been seen for asthma. The primary analysis was the comparison cf the
adherence measures across five study cohorts composed of patients selected on the
basis of one asthma medical daim and one pharmacy daim: LABNICS in combination
(n=563), LABNI CS concurrent (n=224), LABAIanti-leukotriene combination (n=75), I CS
alone (n798), and anti-leukotrienes alone (n=776). The differences in medication
possession ratios (MPR) - defined as the number or days supplied (from first to last
prescription) divided by the treatment duration period (from index date to the exhaustion
of the last prescription) - and refui rates - defined as the number of monthiy (30-day
supply) prescription daims for the cohort regimens over the 12-month follow-up period,
including the index daim - were reported, and ANOVAs adjusting for potential
differences in demographic and baseline measures models were used to statistically
test the differences in treatment days, MPRs, refuI rates, and mean short-acting f32-
agonist use across cohorts. Ail analyses controlled for cohort demographics, physician
specialty at index, pre-index total health care costs, and pre-index asthma medication
use which contributed to minimize the risk 0f confounding. Patients who were
prescribed combination LABNICS obtained significantly more refuIs (4.06) compared to
fluticasone prescribed with salmeterol concurrently (2.35). Findings from Stoloif et al.25
confirm that subjects refihled their ICS almost twice as often if it was combined in the
same device with a LABA rather than the two being prescribed in separate devices.
Therefore, the utilization of a single inhaler containing both an ICS and a LABA may
increase the Iikelihood that patients would not only obtain optimal ICS therapy, but also
benefit from the additive effects of the LABA.
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More recently, a similar study by Stempel et al.26 confirmed the results from the
Stoloif study, documenting that adherence profiles of ICS/LABA in a single inhaler are
significantly better when compared to ICS and LABA in separate inhalers, and
compared to the other regimens. The methodology was similar to the one in the Stoloif
study, except for the addition of an inclusion criteria fat least one SABA daim) by
Stempel et al. and a slightly higher number of subjects (n35D3). In both studies, the
cohorts were similarly identified on the basis of the index medication with unequal
numbers of patients between groups. Stempel et al.26 found that the mean number of
prescription refills for ICS/LABA combination (3.98) was significantly higher than ICS
(2.29) and the ICS component of ICS/LABA f2.36) and ICS/anti-leukotrienes f2.15). No
significant differences were observed between combination and anti-leukotrienes refill
rates f433). The mean number of treatment days was greater for combinations
compared to ICS, ICS/LABA concurrent, and ICS/anti-leukotrienes.
The strengths and weaknesses are similar in both studies. The use of refill rates
from a large database is particularly important to assess prescribing and utilization
trends in clinical practice. it is important however to ensure that the cohorts are
homogeneous for comparison purposes. The selection of patients on the basis of
having a prescription of one of the various regimen types at index date may have
introduced a potential selection bias where patients could experience different levels of
severity across cohorts; patients may not be newly treated with a combination or a
concurrent therapy at the beginning of the follow-up period. In both the Stoloif et al. and
the Stempel et al. studies,2526 patients on concurrent therapy might have been treated
for a longer period of time than patients on combination therapy at the beginning of the
12-month observation period, since LABA arrived on the market a few years before the
combination therapy. Furthermore, the tendency for persistence to decrease over time45
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might resuit in a bias when comparing adherence between patients using combination
or concurrent therapy.
Adherence and persistence to treatment
Suboptimal adherence and poor persistence ta treatment are wideiy spread across
ail major diseases, and it has been shown that survival’ on the prescribed medication
decreases sharply in the first six months of treatment”4 In Canada, the economic
consequence of non-persistence (direct and indirect costs) in terms cf preventable
negative outcomes attributed to the premature treatment discontinuation, have been
estimated around $7-9 billion per year.H5
Non compliance is particularly critical in chronic disease and has been qualified as a
major therapeutic challenge.15 The complexity of the regimen is inversely related to
compliance across a spectrum of therapeutic classes.15 Furthermore, decreased
medication compliance is observed with extended duration cf treatment,H6i7 while
other factors such as level of education, lQ, social status, and other demographic
variables have not been found to correlate with medication compliance rates.18
Adherence, formerly referred to as compliance, is a patient-centered term. It suggests
that patients carry out and maintain certain behaviors, such as taking medications, after
making an informed choice in a supportive environment.”8 Persistence, or continuing to
take a prescribed regimen over a period of time, is also critical for chronic disease
therapies.h16H9 Poor persistence is reflected in the finding that on average 30-50% cf
patients with chronic diseases will not continue to follow drug treatments, as prescribed
by their doctor, over time.120’121 Some examples of factors related ta noncompliance and
inhaled drugs include patients taking long-term medication who stop treatment if they
have not experienced an attack for an extended period.122 The degree of suboptimal
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adherence is also documented in the literature, with up ta 80% of patients expected to
be non-adherent ta their treatment regimen at a given time.120121123
A review of published electronic monitoring data of compliance — defined by most
publications as the proportion of days with the appropriate number of doses taken —
showed that the mean dose taking compliance rate similarly ranged from 70% ta 80%
across ail therapeutic areas, except for respiratary diseases where the rate was doser
to 50%.15
The documented relationship of poor adherence to increased morbidity and even
mortality further highlights the importance of patient adherence ta prescribed asthma
medication therapy.54575859124 A literature review by Cochrane et al.111 found that
asthma patients took the recammended ICS doses of inhaled medication on 20% to
73% of days and that the frequency of efficient inhalation technique ranged from 46% ta
59% of patients. Overall, Cochrane et al. concluded that only a small percentage of the
prescribed dose of an ICS is likely ta reach the target organ, the lung, because of
patient noncompliance with the prescribed dose, difficulty in correct use of the inhaler,
and the ability of a properly used inhaler ta essentially deliver the drug ta the lung.
Compliance with ICS therapy is often thought ta be poor, and worse than with
bronchodilators, probably due ta the absence of immediate relief or perceptible effect
from ICS compare ta short-acting 32 aganists.125 At least twa studies126127 support the
view that inhaled corticosteroid adherence appears ta be warse than adherence with
inhaled 132 agonists. However in bath studies,126’127 the 132 agonists were probably
short-acting, and it was not clear if similar resuits would be found if adherence with ICS
is compared ta long-acting 132 agonists.128 Compliance with ICS was subsequently
shown ta imprave with concomitant use of long-acting beta2-agonists.129 Another
prescription analysis later showed that mean adherence ta new start monotherapy ta
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ICS was 33.8% and to inhaled long-acting 132 agonists was 40%, with adherence
increasing along with the use of short acting 132 agonists,’3° hence perpetuating the view
that persistence appears to be Iower with 10$ than with 132 agonists and that adherence
to inhaled asthma therapies is generally low whether ICS are taken alone or in
concomitant use with 132 agonists.
Although routine use of ICS can markedly improve symptoms and reduce
asthma complications,65’51”3’ the contribution of an overall less than perfect adherence
to ICS (approximately 5Q%)h13124 among aduit patients with asthma could stili be
correlated with several poor asthma-related outcomes. Williams et al.’24 found that
adherence to ICS was significantly and negatively correlated with the number of
emergency department visits (correlation coefficient [ R J = -0.159), the num ber of fills 0f
an oral steroid ( R = -0.179), and the total days’ supply of oral steroid f R = -0.154).
After adjusting for potential confounders, including the prescribed amount 0f 10$, each
25% increase in the proportion of time without ICS medication resulted in a doubling of
the rate of asthma-related hospitalization (relative rate, 2.01; 95% Cl, 1.06-3.79). In a
more recent study using electronic devices to measure compliance to 10$ in patients
with asthma, it was found that on average, patients took 72% +1- 24% of their
prescription. Among the potential predictors of noncompliance to 10$ in adults with
asthma, age was the only significant predictor (compliance increased with increasing
age).’32 A recent review of the literature’28 summarized the determinants of patient
adherence to an aerosol regimen for the treatment of asthma as follows: complexity of
the inhalation regimen (dosing frequency, number of drugs), route of administration (oral
vs. inhaled), type of inhaled agent (corticosteroid adherence is worse than with short
acting 132 agonists), patient awareness of monitoring, as well as a variety of patient
beliefs and socio-cultural and psychological factors. In a study specifically assessing
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these determinants,133 favorable attitude toward ICS was associated with
greater
adherence.
Measures of persistence and adherence in asthma
Most of the earlier compliance research has evaluated measures of medication
consumption for randomized clinical trials of drug therapy.134 The measur
es of
persistence and adherence in asthma vary according to the different stu
dies or
interventions. A clear distinction must be drawn between medications tha
t are
prescribed, medications that are dispensed, and medications that are actual
ly taken.
About one in seven prescriptions are flot cashed in and dispensed1
35, and
nonadherence to prescription instructions, both intentional and nonintent
ional, is
widespread.136’137 Accurate data on both what is prescribed and what s
taken is
required, as weB as information about individual beliefs and behaviors
around
medication taking.138 The relationship between the duration of drug action and tim
ing of
doses, which has a critical impact on the efficacy of treatment, can only be as
sessed by
measures of dose-timing such as electronic medication monitors.139 Covert
electronic
monitoring of inhalers is the gold standard, but this approach has been utilized i
n only a
few small studies because it requires specialized electronic devices)40141 Other
methods for assessing adherence or persistence to asthma inhaler include pa
tient self
reporting in diaries and weighing of used canisters, but these methods
may be
respectively subjective or inaccurate. MacDonald and colleagues142 have identified
several different approaches for measuring adherence or persistence (see Table 5 on
page 83), ranging from more subjective techniques such as health care scales, 10-item
checklist for inhaler use, and self-report scales, to objective daims database analyses.
Results of a systematic review showed that few articles described the develo
pment or
use of self-report methods to measure change in medication over time
. No
questionnaire that was commonly used for this purpose could be found, nor one
that
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had been evaluated and published. Considerable work has been undertaken to develop
questionnaires or diaries for individual projects, but because these tools and their
validation are rarely published, they are flot available for other researchers to use, and
comparison across studies is difficult.138 Overestimation of people’s accounts in self-
reports might bias the resuits of medication adherence studies; patients may be affected
by the context of the interview or questionnaire, such as a desire to please or to be seen
as “good patients”138 by giving a socially acceptable response. Moreover, a
questionnaire such as The Monash Respiratory Questionnaire143 includes lists of
possible asthma medication and two columns of tick-boxes to check for regular use or
use during an asthma attack, but the validation of this format is flot clearly described
and it has flot specifically been developed to measure adherence to treatment.
Physician reports in medical charts might be biased by unawareness of patient
behavior, provider self-presentation, or liability concerns, although data on the accuracy
of chart entries remains fairly sparse.144 Collateral ratings (eg, by spouses or health
professionals) can be useful but may vary in accuracy given the distance from the
patient’s daily activities.145 For instance, electronic monitoring of nebulizer use provides
a more precise measure of long-term medication use than does self-report on diary
cards.146 Pili counts and tests such as blood assay can be useful as long as patients do
not dispose of or consume medication just before it to appear com pliant.147
Overail, there seems to be no one adherence measure against which to calibrate
others, making concurrent validation difficuit. Adherence research in clinical settings is
limited by challenges; respondent burden can be a concern and certain measurement
strategies are limited to certain regimens (eg, piil counts for medication) or have
different meaning with different regimens.148 Pharmacy refui data is iikeiy to be an
accurate representation of what is actuaily taken, especiaiiy for iong-term medication
that is measured over many months.138 Refui compliance studies using databases could
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be characterized by three attributes: (1) the distribution of the compliance variable
(continuous or dichotomous); (2) the number of refUi intervals evaluated (single or
multiple); (3) the use of the measure to assess either the time period over which
medications were available to the patient or the time intervals during which gaps in
therapy occurred.149 Refui compliance measures have a major role in population-based
studies that must assess drug exposure retrospectively, or that cannot employ more
precise measures of medication consumption.149 Other measures of compliance, in
particular electronic monitoring, are more suitable for clinical trials of drug therapy and
for evaluation of drug efficacy when the timing of drug doses is likely to affect patient
outcomes.149
Patients’ satisfaction with their medication predicts continuance of
pharmaceuticai treatment, correct medication use and compliance with medication
regimens.150151 Observationai studies of outcomes of asthma therapy are needed to
understand the implications of choice of controller in different populations.152 It has
been demonstrated that 1CS adherence can be estimated by using prescription refui
information, and that these measures are independently associated with important
asthma outcomes.124 Previous studies evaluated the adherence and/or persistence of
patients using asthma treatment inhalers and showed that compliance to ICS in patients
with asthma is often known to be suboptimai and difficuit to predict.132
It is ptoposed that patients’ decision to continue, alter, or discontinue medical
treatments are influenced by a variety of characteristics, including real or anticipated
beliefs regarding the effectiveness or harms cf treatment.153’154 Therefore, it is
reasonable to suggest that a less compiex treatment regimen, with a faster onset of
action wouid enhance compliance. Hence, the objective cf our population-based cohort
study was to compare both persistence and adherence to treatment between 16-44
years dU asthmatic patients starting a combination and a concurrent therapy, using data
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collected in a large health care insurance database in Canada. The larger sample in our
study compared to similar studies adds statistical power. The drug utilization
comparison between groups was characterized by three different measures to evaluate
persistence and adherence. The use of a one-to-one matching cohort methodology
mitigated the risk for potential confounding; and assessing medication use as an
indicator of severity before including the patients in the cohort contributed to the
homogeneity cf our treatment groups at baseline. To further minimize the potential for
confounding variables, we selected covariates in our Ccx regression analysis based on
an assessment of the most recent or widely used variables in the literature te date.
Since persistence and adherence tend to vary according to treatment duration, the main
strength cf eut study compared to the two other published cohort studies2526 is that
patients needed te be new users of combination or concurrent therapy te enter in our
study cohort.
In this section, we have teviewed the background and rationale that lead te
recommendations cf ICS and LABA therapy for moderate to sevete asthma patients.
This combination has proven better efficacy than ICS alone, considering that LABA
monotherapy is net a recommended therapeutic option. However, persistence and
adherence te concomitant ICS and LABA therapy are generally poor and the literature
particularly underlines the sub-optimal use cf ICS. Data have indicated that simplified
treatment regimen may imprcve persistence and adherence, and this constitutes the
rationale for combining both ICS and LABA in a single inhaler. The scarcity of data to
demonstrate persistence and adherence te this simplified LABNICS inhaler regimen
compared to both medication taken concomitantly has prompted the necessity to
conduct further research in that area.
METHODS
Sources ot Data
This population-based study required access to daims data from the R
égie de
l’assurance maladie du Québec (RAMQ) databases. The RAMQ is the government
body responsible for the administration cf health care services in the Canad
ian province
0f Quebec. These databases contain administrative data files with information on
medical services dispensed to Quebec residents, and on prescriptions filled by the
residents cf Quebec insured by the RAMQ for their medications. At the time cf th
e
study, 43% of the total population of the province of Quebec, Canada155 was insured by
the RAMQ for theit medications. In 1999, the RAMQ drug plan covered over 3,000,000
people classified into three groups: welfare recipients (640,895 individuals), seniors of
65 years dU or more (874,204 individuals), and people from the general populatio
n,
aged under 65 years old who do not have access to a private gr
oup insurance
(1,609,848 individuals). This last group of beneficiaries had been covered by the RAMQ
Drug Insurance Plan since January lst, 1997. The computerized
RAMQ data is
separated into demographics, medical services, and pharmaceut
ical files, each
containing the individuai’s health insurance number, which is the link
between them.
Because the RAMQ plan offers universal medical coverage, both demographic data and
information on medical services are available in the RAMQ databases for ail the
residents cf the province cf Quebec, representing approximately 7.3 million individuals.
The demographic file lists age, gender, postal code and year 0f de
ath. The
medical services file includes daims data on inpatient or ambulatory
medical services
such as: site cf medical practice (outpatient clinic, emergency departme
nt,
hospitalization); nature cf the medical act, date, diagnosis (lCD-9 codes); as well as the
encrypted identification and physician’s specialty.156 The pharmaceutical file
, which has
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been validated for research and previously used for peer-reviewed publications of
pharmacoepidemiologic research studies,157”58 contains data on prescriptions filled at
community pharmacies: drug name, date, dose, quantity, dosage form, and duration as
indicated by the pharmacist, as well as the encrypted identification and prescribing
physician’s specialty. The different RAMQ drug codes for anti-asthmatic medications
appear in Table 1 on page 74.
Study Population
A retrospective study looks backwards and examines exposures to suspected
risk or protection factors in relation to an outcome that is established at the start of the
study. This retrospective, observational, drug utilization study is based upon a cohort of
patients with known exposures to combination (LABA and ICS in the same inhaler) or
concurrent therapy (LABA and ICS prescribed in two different devices, within a plus or
minus 15-day interval), who are followed over a period of time. AdvairTM (salmeterol
xinafoate/ fluticasone propionate) was the first combination therapy approved by Health
Canada in November 1999 and the second combination therapy Symbicort®
Turbuhaler® (budesonide/eformoterol) was granted approval in February 2002. The
cohort was established by selecting asthma patients who were beneficiaries of the
RAMO Prescription Drug lnsurance Plan. New users of combination therapy and new
users of LABA and ICS concurrently were selected from the RAMQ database between
January 1, 1999 and September 30, 2002. New users were defined as patients who
had not received a combination therapy or a LABA for at least one year before the date
of the first prescription of a combination therapy or the date of the first prescription of
concurrent therapy of both LABA and ICS filled on or after January 1, 1999.
A cohort of 12,386 patients was identified on the basis of eligibility criteria : at the
time of inclusion in the cohort - which corresponded to the date of the beginning of a
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combination or a concurrent therapy - subjects were required to be: (1) Aged between
16 and 44 years old inclusively; (2) lnsured under the Quebec drug plan in the
preceding year and at least 30 days following cohort entry; and (3) Exempt of any
recorded prescription for a combination therapy, a concurrent ICS and LABA therapy, or
a LABA monotherapy in the preceding year. This latter exclusion criteria ensures th
at
patients selected in the cohort are really new users of either the combined or concurren
t
LABNICS regimen. Patients could have been on ICS alone since this is the first-lin
e
therapy for asthmatic patients and in the Canadian guidelines LABA is onl
y
recommended as an add-on therapy for those patients who cannot achieve asthma
control on ICS alone.2 If patients had used a LABA in the year preceding their entry i
n
the cohort, they could likely have been on concurrent therapy and would therefore
not
correspond to the definition of new users. The lower limit of our selected age group i
n
the first eligibility criteria is determined in line with the RAMQ categorization for aduits.
The higher limit ensures that chronic obstructive pulmonary disease patients a
re
excluded from the cohort as the onset of that disease typicaly occurs in individuals in
their mid-40s, and distinguishing between asthma and COPD is difficult and may b
e
impossible in some older patients.159 For each patient included in the cohort, we
obtained from RAMQ socio-demographics data, physician characteristics, and data on
aIl filled prescriptions and medical services dispensed between January 1, 1998 and
December3l, 2002.
From the 12,386 individuals who met the eligibility criteria, a final one-to-one
matched cohort was formed (n=5,118). The one-to-one combination to concurrent
matching was based upon: (1) markers of asthma severity: number of prescriptions of
ICS filled in the year preceding cohort entry, and daily dose of ICS prescribed at cohor
t
entry (i.e. first prescription of the combination or concurrent therapy) and (2) markers cf
asthma control: number of prescriptions of oral corticosteroids and short-acting f32-
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agonists filled in the year prior to cohort entry. Matching on ICS
prescriptions refuis and
seiecting patients who have aiready consumed ICS in the year pre
ceding their entry in
the cohort would not affect the primary outcome measure
of the study because
persistence and adherence are assessed for patients who s
tart a new regimen
consisting of both LABA and ICS taken together, whether the
regimen us administered
with a single inhaler or with two inhaling devices. Unmatched
users of concurrent or
combination therapy were not inciuded in the study. The one
-to-one matching was
aimed at ensuring equal distribution of confounders amongst bo
th study groups, more
specificaily in terms of asthma control and severity.
Subjects were followed until the earliest of these events: December 31, 2002,
death, a switch between a concurrent and a combination thera
py, or loss of coverage
under the drug insurance plan.
Drug Exposure and Persistence
The concurrent therapy was reconstructed by using an algorithm
based on the
dispensing date, amount dispensed, duration of treatment, an
d the name of the
medication. Patients considered in the concurrent group had
refilied prescriptions of
ICS (beclomethasone, fluticasone propionate, budesonide) and LABA
(saimeterol,
formoterol) within an interval of 15 days between the dispensing dates.
Patients
considered in the combination group were simply identified
if they had one filled
prescription for that treatment (fluticasone propionate/salmetero
l or
budesonide/formoterol) since a single inhaling device combines both age
nts. The
rationale behind selecting new users is based on the knowledge
that persistence and
adherence tend to vary over t1me160; if patients would already be
treated with one cf the
regimen under study before entering the cohort, it may have an
influence on the study
outcome. AIl new users of combination therapy were included in
the study with the
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consideration that this regimen only became available in the market as 0f November
1999. Consequently, new users of concurrent therapy may have been on their
treatment regimen for a longer duration during the study period, prompting the necessity
to adjust for previous adherence in a multivariate model.
Assessing failure to refui prescriptions constitutes a reliable and objective
measure of persistence in large patient groups.149 The primary outcome of persistence
was defined as having prescriptions of the ongoing therapy continuously renewed within
a pre-specified grace period (time window). This grace period for renewal was defined
as the sum of three times the duration of the current prescription (in days) plus ail
overlaps accumulated since the beginning of the therapy. An overlap was considered
when a patient refilled a prescription before its end; for exampie, a 30-day prescription
dispensed on January lst (end date equal to January 30) and refilled on January 15,
wouid generate a 15-day overlap. For patients who did not persist on treatment, the
discontinuation date was the last day of drug suppiy, that is the end date of the iast filled
prescription plus ail overlaps since the beginning of the therapy. For concurrent
patients, a discontinuation was observed if they ceased either both prescriptions of
LABA and ICS, LABA alone, or ICS alone.
Determinants of Persïstence
Potentiai determinants of persistence pertaining to the patients’ characteristics
included age (5-year differential), gender (male versus female), receipt of social
assistance (yes/no), atea of residency (urban versus rural), and the average number of
different medications at cohort entry. Markers of asthma severity and control were
also considered as potentiai determinants of persistence: prescribed daiiy dose 0f ICS
( 250, > 250 - 500 and > 500 mcg of fluticasone or equivalent) at cohort entry,
number of prescriptions fiiled in the year preceding cohort entry for 1CS, oral
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corticosteroids, and short-acting 32-agonists; hospitalization for asthma (yes/no); visit
to an emergency room for asthma (yeslno), and medical visits to a respiratory
physician for asthma (yes/no), ail in the year prior to cohort entry. As potential
determinants of treatment persistence, we also identified the prescribing physician’s
specialty (general practitioner, respiratory physician, or other specialist) at cohort
entry; and assessed whether individuals had records for at least one prescription of
anti-leukotrienes (yes/no) or theophylline (yes/no) in the year prior to cohort entry.
Patient’s Adherence
Three indicators of patient’s adherence were calculated and compared between users
of
each therapy group using t-tests.
First, the average number of prescriptions of combination or concurrent therapy
filled per patient during the year foliowing cohort entry. For patients under concurrent
therapy, adherence is caiculated as the average adherence for the LABA and ICS,
in
une with the definition of concurrent (prescribed within +1- 15 days). This calculation
indicates in which treatment group, combination or concurrent, patients have the most
refuis.
Second, the average number of days under either therapy with the prescribed
dose during the year following cohort entry (i.e. sum of drug supply days of ail
prescriptions filled during that year, with censoring of the last prescription if it cross
es
the end of the year). This measure provides a gross indicator of the drug utilization
pattern during the first year of treatment, indicating in which groups patients have m
ore
days of treatment under the prescribed medication. These two measures wer
e
caiculated among patients who were followed for at least one year
Third, as the main measure of adherence, we calculated the percentage of time
patients took the prescribed dose, while persistent to the therapy under study (sum of
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drug supply days between the first and Iast fui dates divided by Iength 0f drug
therapy)’61. This measure of adherence was calcuiated among patients who filled at
ieast two prescriptions 0f either combination or concurrent therapy during the study
period. This constituted our main measure of adherence because it considered the time
during which patients had persisted on treatment during the study period. In contrast
with the two first measures which were performed on individuais who had been foiiowed
up for at ieast one year, it was important to evaluate adherence in the context of
persistence, to have a measure of adherence that was independent of the persistence.
Thus, this third measure refiects both persistence over time and adherence to the
prescribed medication.
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Statistical Analysis
Statistical power and sample size
At the design stage cf any investigation, it is cemmon practice to minimize the
probabiiity cf failing te detect a reai effect (type II errer, faise negative). The prebability
of type Il errer is equal te one minus the power cf a study (probabiiity cf detecting a true
effect). In otder te do so, eut study protocoi inciuded a seiected power levei for our
study, along with the two-sided significance ievei at which we intended te accept or
reject nuli hypetheses cf our statisticai tests. The significance level (5%) is the
prebabiIity cf type I errer (incorrectly rejecting the nuil hypothesis, faise positive).
Befere selecting patients from the cohert, we used the PASS statisticai and power
analysis software162 te perform a Two Proportions Power Analysis te estimate the
required sampie size. The type I errer a was set te 0.05, the power cf the bilaterai test
was set te 0.90 and we estimated that the proportion cf patients who refiiled their
prescription at ieast once within the year follewing the index date would be cf 40% for
the concurrent therapy (LABA + ICS) patients, based en the cempiiance range found in
the literature. More specificaiiy, this estimated proportion cf patients who refui their
prescription was based on previeus asthma study with similar methodoiogy in which it
was found that 38% of ICS patients renewed their prescription at Ieast once within the
year following the initiation cf the ICS therapy)13 The output generated by the PASS
software indicated that group sampie size cf n = 831 wouid be required te detect a
difference cf 20% between the concurrent therapy and the combination therapy, that is a
net difference of 8% between the estimated proportion cf patients that wouid persist in
their concurrent therapy vs. combination therapy. PASS was aise used to estimate the
sampie size required in each group te demenstrate a difference in the probabiiity te
remain on the medication regimen under study. A Log-Rank Survivai Power Anaiysis
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was performed assuming that 75% of patients will be censored, at a power of 0.90, and
an alpha etror of 0.05. The output of PASS showed that group sample size in both
groups should be of n = 2100 to be able to show an absolute difference of 5% one year
after the initiation of the compared therapies.
Estimation and comparison of treatment persistence
Treatment persistence between concurrent and combination groups was compared
using three analyses.
Firstly, we estimated the proportion of patients without prescription refuI during
the year following the beginning of therapy, and compared these proportions with a khi-
square test. This analysis was restticted to patients who had at least one year of foflow
up.
Secondly, the cumulative persistence rate was estimated using the Kaplan-Meier
failure time analysis.163 This method estimates survival rates, expressed as the survivor
function (S), which corresponds to the number of individuals surviving longer than time
(t), divided by the total number of individuals studied. Time (t) can be the survival time,
time-to-event or time to failure such as treatment discontinuation in our study. Kaplan
Meier curves plot percent survival as a function of time.
Survival analysis methodology, such as the Kaplan Meier analysis, consists of a
set of procedures useful for analyzing experiments where the response variable is the
time until the occurrence of an event of interest (discontinuation of treatments under
study). The main characteristic of survival data is the presence of censoring, which is a
partial observation of the response, where some individuals are free from the event due
to the end of the study, or due to being withdrawn according to censoring criteria. This
method automatically accounts for censored patients, as both the numerator and
denominator are reduced on the day a patient is censored. Day I is the first day of the
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study for each subject. As the event of interest ïs usually flot observed for ail subjects
due to, amongst other reasons, the end of the study, a corresponding censoring
indicator is defined to indicate whether the event has occurred or flot. it is usual to
assume the value 1 when an event has occurred within the follow up period and O
otherwise164. Censored subjects contribute to the data up until the time of censoring,
but contribute no data after that. This method assumes that censored individuals have
the same prospect of survival as those who continue to be followed.
In our study, non-persistence was considered if there was no renewal within a pre
defined grace period following the date of the latest prescription. The Kaplan-Meier
curves were compared between both regimens using log-rank tests165. For patients
using the concurrent therapy, we also estimated Kaplan-Meier curves for ICS and LABA
separately and then, compared these curves with the log-rank test. It is common to
compare two survival curves between two treatments using log-rank tests. The log-rank
test function provides methods for comparing survival curves where some of the
observations may be censored and where the overail grouping may be stratified. These
methods are nonparametric in that they do flot make assumptions about the
distributions of survivai estimates or hazard curves. The nulI hypothesis tested here s
that the risk of treatment discontinuation is the same in both groups. For each time
interval, the observed number of discontinuation in each group is compared with the
expected number of discontinuations if the nulI hypothesis were true. Ail the observed
and expected values are combined into one khi-square statistic and the p-value is
determined from that.
Thirdly, the Cox Regression Model was used to further compare the probability
of non-persistence between both drug regimens (combination versus concurrent
therapy), while adjusting for the potential determinants described above. Cox
40
regression model (Cox, 1972) is without any doubt the most popular model used for
lifetime data analysis164. When the hazard function depends on time, hazard ratios can
be estimated after fitting a Cox’s proportional hazards model which assumes that for
each group the hazard functions or failure rates are proportional at each time (no
particular distribution function assumed for the hazard function). In other words, if an
individual shows a risk of failure equal to three times the risk of failure of another
individual in the beginning of the study, then this ratio will be the same for any other time
t during the follow-up period164. The purpose of using the Cox regression model is to
estimate the survival curves and assess the importance 0f these predictors upon the
response variable; namely time until discontinuation in our study (modeling predictors’
effects on survival data via the hazard function). Predictors can be a number of factors
that are thought to be related to the event under study. The number of factors to be
considered depends on the purpose of the study and they can be qualitative (sex, place
0f residence, gender, etc.) or quantitative (age, drug utilization, etc.).166 The hazards
ratio associated with a predictor variable is generated; along with a confidence interval.
The hazards ratio may also be thought of as the relative discontinuation rate. If the ratio
value is inferior to 1, the likelihood of treatment discontinuation for the patients exposed
to the combination therapy is inferior to the likelihood of discontinuation for patients in
the other group (concurrent therapy); the exposure to combination therapy is then found
to be a protective factor of treatment discontinuation. For example, with a hazard ratio
0f 0.83 (adjusted for ail the variables considered in the regression analysis),
combination users would be 17% less likely to stop their treatment as compared to
concurrent users (adjusted hazard ratio 0.83; 95%Cl: 0.78-0.88). Conversely, if the
value of the ratio would be superior to 1, there would be a higher risk of discontinuation
for patients in the combination therapy group than for those in the concurrent therapy
group; exposure to combination therapy would have been considered as a factor that
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may increase the outcome of treatment discontinuation. If the ratio would be equal to 1,
the interpretation would be that there is no significant association between exposure to
the combination therapy and treatment discontinuation. If the value 1 is not in the range
of the confidence intervals that are also generated with the Ccx regression analysis,
then it can be concluded that the proportions are significantly different in the two groups,
and there is an increased tisk in one group compared to the other.
In order to determine the predictors of treatment discontinuation, the hazard ratios in our
Cox regression model adjusted for ail the co-variables included in the model, on the
basis of the first variable (treatment under study). Four categories of co-variabies
considered as potential determinants for treatment discontinuation were included in the
model: (1) socio-demographics (age 5-year difference, gender, socio-economic status
as defined by access to social assistance from the Quebec government, place cf
residence (urban or rural), (2) initial prescription of combination or concurrent therapy
(prescribing physician’s specialty for the first intention cf treatment by which cohort entry
was determined and initial average daily dose ICS in micrograms cf fluticasone
equivalent 250, >250-500, >500), (3) drug utilizaticn (for each additional prescription
cf ICS, oral ccrticcsteroids and short-acting f32 agonists; prescription cf theophylline and
anti-leukotrienes (yes/no); and number cf different medications expressed for each
additional prescription in the year preceding cohort entry), (4) health care services
utilization (hospitalizations, emergency, due te asthma, or GP or respirologist visits for
asthma) in the year preceding cchort entry. Health services utilization was measured by
calculating the number cf prescribing physicians and medical visits recorded during the
year preceding cohort entry; except for the number of hospitalizations which was
restricted te the year preceding index date.
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Sensitivity analysis to test the grace period
We performed a sensitivity analysis to test the impact of the pre-defined grace
period, by re-estimating persistence for bath therapy groups using different grace
periods, defined as twa and fout times the duration of the Iatest prescription plus ail
overlap periods accumulated since the index date. For example, if the duration of the
prescription recorded in the drug database was of 30 days and the patient had
accumulated 15 days 0f overiap since the index date, then the grace period would be of
75 days ((30 x 2) + 15). We performed a Kaplan-Meier anaiysis with these alternative
grace periods for treatment renewal ta assess their impact on persistence and the iog
tank test was used ta compare persistence on LABA5 and ICSs used concurrently with
persistence ta combination therapy based on these longer and shorter grace periods for
treatment renewal.
Estimation and comparison of treatment adherence
Adherence ta the prescribed therapy — namely the average number of
prescriptions filied per patient, the average number of days under therapy during the first
year of follow-up, and the average percentage of time patients took the prescribed dose
while persistent to the therapy — was compared between users of each therapy group
using t-tests. Among concurrent users, measures of adherence were also estimated for
ICS and LABA separately. Based on the number of patients followed for at ieast one
year, we determined for each treatment group the mean number cf filled prescriptions
per patient and the mean number of days on prescribed medications during the first year
cf treatment and determined the p-value for each comparison between the twa groups.
Treatment adherence ta the prescribed therapy whiie persistent was calcuiated in each
group based on the number of patients with at least twa filled prescriptions. The mean
0
percentage of days with the prescribed dose was determined for each group and the p
value was generated to assess the statistical significance between the two groups.
Ail analyses were performed on Statistical Analysis System Software (8; SAS
Institute, Cary, North Carolina).
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ABSTRACT
Background: Limited evidence exists on persistence and adherence with asthma combination
regimens including both inhaled corticosteroids (ICS) and long-acting 32-agonists (LABA) wïthin
the same inhaler (combinations) compared to these medications inhaled separately
(concurrents).
Objective: b compare persistence and adherence between 16-44 years old asthmatic patients,
starting combination or concurrent therapies.
Methodology: This retrospective one-to-one matched cohort is based upon daims data. Newly
treated asthmatics with either a combination or concurrent therapy were selected from the Régie
de l’assurance maladie du Québec (RAMQ) database between January 1999 and December
2002. Combinations were one-to-one matched to concurrents using control and severity
markers in the year prior to cohort entry. Persistence was determined by a Kaplan-Meier
analysis. Cessation probability between groups was assessed using a Cox Regression model,
adjusting for socio-demographics and markers of asthma control and severity. Adherence was
estimated by the time patients were on the prescribed therapy.
Resuits: Persistence with combinations felI to 10% 12 months after initiation, down to 5% over 2
years while concurrents’ rates declined from 5% to below 2%. Persistence was better with
combinations (adjusted hazard ratio for discontinuation (0.83; 95%CI: 0.78-0.88). Concurrents
stopped LABA slightly more than ICS (p-value <0.0001). Average days under treatment duting
the first year was significantly higher with combinations (90.4 vs. 73.1; p<0.000l). Treatment
adherence was slightly lower in combinations vs. concurrents (55% vs. 58%; p0.0031).
Conclusion: Combinations were slightly more persistent than concurrents, but slightly less
adherent. Persistence to inhaled controller therapies is very low among adult asthmatic patients.
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INTRODUCTION
The international guidelines (GINA)1 and latest Canadian consensus2 uphold the concept
of asthma management as a continuum, contingent on underlying symptoms severity and
pulmonary tests results. When asthma is not optimally controlled with inhaled corticosteroids
(ICS) alone, the addition of longacting 32-agonists (LABA) to ICS is accepted as the most
effective therapy to control moderate to severe asthma.3 This therapeutic approach is also
supported by NAEPP guidelines4.
ICS and LABA have a complementary effect,567’8 treating both underlying airway
inflammation and obstruction, respectively
3910• It has been shown that this regimen provides
greater control than increasing the dose of lCS1 and may also improve outcomes (lung
function, exacerbation rates, and quality of life) in asthmatics who remain symptomatic on ICS.13
Concurrent or combined administration of ICS and LABA may not be equivalent.
‘Concurrent’ entails the manipulation 0f two different inhalers (one for each drug) whereas
‘combination’ involves a single inhaler (containing both agents).14 Moreover, evidence suggest
that ICS and LABA in a single inhaler may be superior in reducing asthma exacerbations than
the administration of the same products in two separate inhalers.15
Furthermore, adherence to asthma treatments declines as the regimen becomes more
complicated, either by increasing the number of medications and/or the number of daily
doses.1617 Consequently, it has been hypothesize&819 that the use of combination inhalers can
improve patient’s adherence, which may lead to overall asthma control.20’21’22 Only one
published study23 so far has tested this hypothesis in usual care clinical practice in the US.
Therefore, we performed a population-based cohort study to compare treatment
persistence and adherence among asthmatic patients between the ages of 16 and 44, who were
starting a combination or a concurrent therapy. The data was obtained from a large health cate
insurance database in Canada.
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METHODS
Sources of Data
This population-based study required access to daims data from the Régie de
l’assurance maladie du Québec (RAMQ) databases. These contain administrative data files on
residents covered by the provincial health care and by the public drug insurance plans, including
about 43% of the total population of the province of Quebec, Canada.24 The computerized data
is separated into demographics, medical services, and pharmaceutical files, each containing the
individual’s health insurance number, which is the link between them.
The demographic file lists age, gender, postal code and year of death. The medical
services file includes daims data on inpatient or ambulatory medical services such as: site of
medical practice (outpatient clinic, emergency department, hospitalization); nature of the medical
act, date, diagnostic (lCD-9 codes); as well as the encrypted identification and physician’s
specialty.25 The pharmaceutical file, which has been validated for research and previously used
for pharmacoepidemiologic research studies,2627 contains data on prescriptions filled at
community pharmacies: drug name, date, dose, quantity, and duration as indicated by the
pharmacist, as well as the encrypted identification and prescribing physician’s specialty.
Study Population
A cohort of 12,386 patients was identified from the RAMQ database between January 1,
1999 and September 30, 2002 on the basis of eligibility criteria. At the time of inclusion in the
cohort - which corresponded to the date 0f the beginning 0f a combination (LABA and ICS in the
same inhaler) or a concurrent therapy (LABA and ICS prescribed in two different devices within
a plus or minus 15-day interval) - subjects were required to be: (1) Aged between 16 and 44
years old inclusively; (2) lnsured under the Quebec drug plan in the preceding year and at least
30 days following cohort entry; and (3) Exempt of any recorded prescription for a combination or
a concurrent ICS and LABA therapy in the preceding year. For each patient included in the
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cohort, we obtained from RAMQ socio-demographics data, physîcian characteristics, and data
on ail filled prescriptions and medical services dispensed between January 1, 1998 and
December3l, 2002.
From the 12,386 individuals who met the eligibility criteria, the final one-to-one matched
cohort was formed (n=5,118). The one-to-one combination to concurrent matching was based
upon: (1) markers of asthma severity: number of prescription of ICS filled in the year preceding
cohort entry and daily dose of ICS prescribed at cohort entry (i.e. first prescription of the
combination or concurrent therapy) and (2) markers of asthma control: number of prescriptions
of oral corticosteroids and short-acting f32-agonists filled in the year prior to cohort entry.
Subjects were followed until the earliest of these events: December 31, 2002, death, a switch
between a concurrent and a combination therapy, or loss cf coverage under the drug insurance
plan.
Drug Exposure and Persistence
The concurrent therapy was reconstructed by using an algorithm based on the
dispensing date, amount dispensed, duration cf treatment, and the name of the medication.
Patients considered in the concurrent group had refilled prescriptions of ICS (fluticasone,
budesonide, beclomethasone) and LABA (salmeterol, formoterol) within an interval of 15 days
between the dispensing dates. Patients considered in the combination group were simply
identified if they had one filled prescription for that treatment (fluticasone propionate/salmeterol
or budesonide/formoterol) since a single inhaling device combines both agents.
Assessing failure to refui prescriptions constitutes a reliable and objective measure of
persistence in large patient groups.28 The primary outcome of persistence was defined as
having prescriptions cf the ongoing therapy continuously renewed within a pre-specified grace
period. This g race period for renewal was defined as the sum of three times the duration of the
current prescription (in days) plus ail overlaps accumulated since the beginning cf the therapy.
An overlap was considered when a patient refilled a prescription before its end; for example, a
30-day prescription dispensed on January lst (end date equal to January 30) and reflhled on
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January 15, would generate a 15-day overlap. For patients who did not persist on treatment,
the discontinuation date was the last day cf drug supply, that is the end date of the last fiuied
prescription plus ail overlaps since the beginning of the therapy. For concurrent patients, a
discontinuation was observed if they ceased either both prescriptions of LABA and ICS, LABA
alone, or ICS alone.
We examined the impact of the selected grace period by reiterating the persistence
analysis using grace periods based on two and four times the duration of the last prescription
plus any accumulated days of overlaps.
Determinants of Persistence
Potential determinants of persistence included age (5-year differential), gender (male
versus female), receipt of social assistance (yeslno), area of residency (urban versus rural),
c and the average number cf different medications at cohort entry. Markets
of
and control were also considered as potential determinants cf persistence: prescribed daily
dose cf ICS ( 250, > 250 - 500 and > 500 mcg of fluticasone or equivalent) at cohort entry,
number of prescriptions filled in the year preceding cohort entry for ICS, oral corticosteroids,
and short-acting 32-agonists; hospitalization for asthma (yes/no); visit to an emetgency room
for asthma (yes/no), and medical visits to a respiratory physician for asthma (yes/no) in the
year prior to cohort entry. We also considered the prescribing physician’s specialty (general
practitioner, respiratory physician, or other specialist) at cohort entry; as well as records for at
least one prescription of anti-leukotrienes (yes/no) or theophylline (yes/no) in the year prior to
cohort entry as potential determinants of treatment persistence.
Patient’s Adherence
Three indicators of patient’s adherence were calculated. First, the average number of
prescriptions of combination or concurrent therapy filled per patient during the year following
cohort entry. Second, the number of days under either therapy with the prescribed dose during
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the year foliowing cohort entry (i.e. sum of drug supply days cf ail prescriptions filled during
that year, with censoring cf the last prescription if it crosses the end cf the year). These two
measures were calculated among patients who were followed for at least one year. Third, as the
main measure cf adherence, we calculated the percentage of time patients teck the prescribed
dose, while persistent to the therapy under study (sum cf drug supply days between the first and
last fui dates divided by length cf drug therapy)29. This measure cf adherence was calculated
among patients who filled at least two prescriptions cf either combination or concurrent therapy
during the study period.
Statistical Analysis
Treatment persistence between concurrent and combination groups was compared using
three analyses. Firstly, we estimated the proportion cf patients without prescription refui during
the year foilowing the beginning cf therapy, and compared these proportions with a khi-square
test. This analysis was restricted to patients who had at least one year cf follow-up.
Secondly, the cumulative persistence rate was estimated using the Kaplan-Meier failure
time analysis.3° Non-persistence was considered if there was no renewai within the pre-defined
grace period following the date cf the iatest prescription. The Kaplan-Meier curves were
compared between both regimens using log-rank tests31. For patients using the concurrent
therapy, we aise estimated Kaplan-Meier curves for ICS and LABA separateiy and then,
compared these curves with the 10g-tank test. We performed a sensitivity analysis te test the
impact cf the pre-defined grace period by re-estimating persistence for both therapy groups
using different grace periods, defined as two and four times the duration cf the latest prescription
plus overlaps.
Thirdly, the Ccx Regression Model was used te further compare the probability cf non
persistence between both regimens, while adjusting for the potential determinants described
above, and te obtain crude and adjusted hazard ratios cf discontinuation.
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We aise estimated the proportion 0f patients reinitiating a treatment in the year
following the end cf their therapy and compared that proportion between users of the
combination and concurrent therapy with a khi-square test.
Adherence to the prescribed therapy — namely the average number cf prescriptions filled
per patient, the average number cf days under therapy during the first year cf follow-up, and the
average percentage of time patients took the prescribed dose while persistent to the therapy —
was compared between users cf each therapy group using t-tests. Among concurrent users,
measures of adherence were also estimated for ICS and LABA separately.
Ail analyses were performed on Statistical Analysis System Software (8; SAS institute,
Cary, Ncrth Carolina).
RESULTS
The matched cohort ccnsisted cf 5118 patients: 2,259 new users cf a combination
therapy were one-to-cne matched to new users cf concurrent therapy based on the markers cf
asthma severity and control (as described under Study Population). The remaining unmatched
patients (7,268/12,386) were excluded from the analyses.
Patient Characterïstics
Table 1 presents the characteristics cf the matched ccmbinaticn and concurrent therapy
users. Mean age was comparable between groups while the proportion cf men was slightly
higher in the combinaticn group (38.4% versus 35.0%). The number cf combination users
receiving social assistance was slightly lcwer (41.5% versus 47.3%), and fewer cf them lived in
a rural area (21.8% versus 24.0%) than ccncurrent users. The number cf different medications
recorded in the year preceding cohcrt entry was simitar in both groups. During the year
preceding cchcrt entry, the percentage cf patients who had at least one emergency visit (11.1%
versus 15.3%) and hospitalization (2.1% versus 4.3%) for asthma were Icwer in the combinaticn
group than in the concurrent group. The same trend was observed for the percentage cf
patients with at least one visit for asthma with a respiratcry physician in the year preceding
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cohort entry (7.7% for combination versus 16.2% for concurrent) and for the percentage of
patients for whom the first prescription was written by a respiratory physician (7.8% for
combination versus 18.9% for concurrent). By design, patients from both groups had no
prescription of LABA filled in the year preceding cohort entry and in both groups, the average
number of prescriptions filled by patients was 1.4 for ICS, 0.3 for oral corticosteroids and 2.7 for
short-acting j32-agonists in the year preceding cohort entry. In both groups, at cohort entry,
61.8% of patients had a prescription of ICS of more than 500 mcg per day in fluticasone
equivalent.
Treatment Persistence
As a crude measure of non-persistence to treatment, we estimated that 44.2% of the
patients who started a combination therapy and 51.5% of patients who started a concurrent
therapy did not renew their prescription during the first year (p-value= 0.0001).
Figure I presents the Kaplan-Meier curves representing the cumulative percentages of
patients persisting on therapy at different points in time comparing combination (n=2,259) and
concurrent (n=2,259) users, using the pre-specified grace period. The graph shows that
combination users tended to be more persistent on treatment than concurrent users (p-value for
log tank-test < 0.0001). We found that 10% of combination users were still persistent one year
after the initiation of therapy, while this percentage was slightly below 5% for concurrent usets.
The corresponding figures at two yeats for each regimen wete 5% and below 2% respectively.
The sensitivity analyses based on two and four times the duration of the latest prescription plus
overlaps showed that regardless of the grace period definition, patients on combination therapy
were found to be slightly more persistent than patients on concurrent therapy (p-value for log
rank test < 0.000 1 for both g race periods).
We also looked at the persistence on LABA and ICS separately among concurrent
therapy users. This analysis indicates a slightly better persistence rate for ICS as compared with
LABA (p-value for log-rank test < 0.0001). One year after the initiation of the concurrent therapy,
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approximateiy 11% of the patients were stili using their LABA and 13% were stili using their
ICS. These figures were close to 5% for both agents after two years (Kaplan-Meier graph can be
viewed at the Online Repository).
Table 2 lists the crude and adjusted hazard ratios for discontinuation as determined by
the Cox Regression Model. After adjusting for ail potential determinants of discontinuation, we
found that combination users were 17% less likeiy to discontinue their treatment (rate ratio [RRJ
= 0.83; 95% confidence interval [Cl]: 0.78-0.88) than concurrent users. This model also showed
that older patients, men, patients receiving social assistance, and patients taking a greater
number of different medications were significantly less likely to discontinue their treatment. We
also found that patients with markers of asthma severity and lack of control, patients using anti
leukotrienes in the year preceding cohort entry, and patients who had their therapy initially
ç prescribed by a respiratory physician were significantty less iikely to discontinue their treatment
.
On the other hand, patients who received more than 500 mcg of 1CS in fluticasone equivalent at
cohort entry were found to be more likely to discontinue than patients receiving lower doses.
Finally, among patients who stopped their initial therapy according to our definition, we found
that 52% (601/1162) of combination users and 34% (555/1609) of concurrent users re-initiated
their therapy in the year following discontinuation (p-value < 0.0001).
Treatment Adherence
Resuits for treatment adherence analyses are presented in Table 3. We found that during
the first year, the average number of prescriptions filled was 3.5 for combinations and 2.7 for
concurrents (p-value <0.003). We also found that combination users had, on average, more
days of drug supply during the first year than concurrent users (90.5 versus 73.1 days; p-value <
0.003). However, treatment adherence was found to be slightly lower for combination than for
concurrent therapy users (55% versus 58%; p-value <0.003).
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In the concurrent group, we found that the average prescriptions filled during the first
year was 3.5 for ICS and 3.4 for LABA (p-value <0.05). We also found a higher number of
average drug supply days for ICS than for LABA during the first year (100.9 versus 89.8 days; p-
value <0.05). However, adherence was found to be slightly lower for ICS therapy than for LABA
therapy (53% versus 55%; p-value = 0.1238).
DISCUSSION
Patients on a combination therapy were found to be slightly more persistent than patients
treated with ICS and LABA taken in two different inhalers. Persistence with combinations fell to
10% 12 months aftet initiation and declined to 5% over 2 years. For the same time periods,
persistence in the concurrent group decreased from 5% to below 2%. The Cox Regression
c Model showed that combination users were 17% less likely to stop their treatment than
concurrent users. Adherence was also found to be 10w for both regimens: users of combination
and concurrent therapy took on average 55% and 58% of their prescribed doses, respectively.
Our findings are consistent with those of a retrospective cohort study where Stoloif et al.
measured treatment adherence for patients aged 12 years or older, using the number of
prescriptions recorded in a United States daims database over a J2-month period. They
observed that patients who were prescribed LABNICS combination obtained significantly more
refills (4.06) compared with patients prescribed fluticasone and salmeterol concurrently (2.35).
Their study included a smaller number of patients (2511 patients) in a wider range of age groups
than in ours. StilI, the outcome in terms of persistence with combined inhalers was in the same
direction as ours, but the observed difference was larger. One major methodological difference
between that study and ours is that their patients were not newly treated with a combination or a
concurrent therapy at the beginning of the study. In the Stoloif et al. study, patients on
concurrent therapy might have been treated for a longer period of time than patients on
combination therapy at the beginning of the 12-month observation period, since long-acting f32-
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agonists arrived on the market a few years before the combination therapy. As we observed in
our study, persistence tends to decrease ovet time, and this phenomenon might explain why in
the Stoloif et ai. study, combination patients were found to be more adherent whiie concurrent
patients were found to be Iess adherent than in our study, leading to a larger between-group
difference.
In our study, through the Cox Regression Model, we also found that older patients, men,
patients receiving social assistance, and patients taking a larger number of different
medications, were less likely to discontinue their treatment. Markers of uncontrolled and severe
asthma were found to be significant predictors of higher persistence to treatment. However,
patients with a dosage higher than 500 mcg of ICS in fluticasone equivalent at cohort entry were
found to be significantly more likely to discontinue their treatment.
Although using one inhaler instead of two could likely be easier to manage for patients, it
is worthy, as in any observational study, to review the biases that might have distorted the
magnitude of our results. Disease severity and degree of asthma control could affect persistence
on therapy. One may speculate that sicker patients might be more likely to perceive a benefit
from their asthma preventive therapy and thus, be more likely to be persistent. Consequently
and with respect to our study, ail efforts were made to control differences between treatment
groups by matching patients on well known markers of disease severity and control (short-acting
32-agonists, inhaled and oral corticosteroids utilization in the year prior to cohort entry, and on
the prescribed dose of ICS at cohort entry)32’33’34. In order to adjust for any remaining differences
even after matching, we performed a regression analysis including several potential
confounders, such as ED visits and hospitalizations for asthma. Despite matching and
adjustment for potential confounders in the regression modei, we cannot completely rule out the
possibility of residual confounding. Therefore, the study results could be considered as
conservative given that the higher level of severity and lack of control seen in the concurrent
group — based on higher frequency of ED visits and hospitalizations for asthma prior to cohort
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entry and on higher number of different medications at cohort entry — is likely to minimize
differences between the two groups.
One frequent argument in fayot of combination therapy instead of ICS and LABA in
separate inhalers is that patients might be more likely to stop their ICS and continue their LABA,
since they might perceive more easily the benefit of the LABA. However, in our study we found
the opposite: patients who started a concurrent therapy were slightly more likely to stop LABA
than ICS.
Persistence on LABAIICS therapy is essential to prevent exacerbations in patients
suffering from persistent asthma. However, a LABNICS regimen could also likely be prescribed
to treat other conditions; for example, chronic obstructive pulmonary disease (COPD).
Therefore, this issue was minimized in our study by including patients only if they were less than
C 45 years old at cohort entry; thereby exciuding those CQPD patients and considering only
persistent asthma sufferers.
The main strength of this study is that the analyses were performed on a large
population-based administrative database and thus, represent the real-life use of these drugs in
clinical practice, with a large sample size providing high statistical power to the analyses. The
use of an administrative database to measure drug exposure also eliminates the potential of
recall bias35. Moreover, our sensibility analyses results showed that the Kaplan-Meier estimators
were not influenced by the duration of the selected grace period for treatment tenewal;
differences of similar magnitude in the persistence rate could still be observed between groups,
regardless of the grace period.
One weakness of this study is the absence of clinical measures of asthma severity and
control, such as pulmonary function tests and symptoms scores. However, extremely useful
markers of disease severity and control allowed us to match and adjust for the potential
confounding effects of disease severity and control. In addition, because the study was based
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entirely on computerized data of dispensed medications, data may flot coincide exactly with
the actual intake of the medications, potentially resulting in drug use misclassification.35
Our resuits demonstrate that persistence on LABNICS controller therapies presently
used in the prophylaxis of asthma remains very poor among aduit asthmatic patients. Clearly,
many patients take their controller medication sporadically and we should question the impact of
this phenomenon on a patient’s health, as weIl as on the use and cost of health care services.
Overall, the trivial magnitude of the difference in persistence observed in our study with
combination therapy compared to LABNICS in separate inhalers reinforces the importance of
addressing the issue of asthma management beyond merely reducing the complexity of drug
regimens. Whether this slight difference leads to better clinical outcome needs to be
investigated.
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Table 1. Patient’s characteristics for new users cf a combination or a concurrent therapy.
Combination Concurrent
(n=2559) (n=2559)
Socïo-demographic characterïstïcs
Age (in years), mean ± s. d. 32.5 ± 8.2 32.7 ± 8.2
Gender, ¾ men 38.4 35.0
Receipt cf social assistance, % 41.5 47.3
Living maturaI area,% 21.8 24.0
Number cf different medications 6.5 ± 5.6 6.7 ± 5.9
Initial prescription of combination or concurrent therapy
Prescribed daily dose cf inhaled corticosteroid : mcg
mean ± s.d. 761.4 ± 363.7 858.7 ± 467.2
% users
(250 4.3
>250—500 33.8
>500 61.8
Prescribing physician. %
Family physician $7.1 74.4
Respiratory physician 7.8 18.9
Other specialists 5.1 6.6
Use of health care services in the year preceding cohort entry
(1 ED visit for asthma, % 11.1 15.3
(1 hospitalization for asthma, % 2.1 4.3
(1 visit to a respiratory physician for asthma, % 7.7 16.2
Visits to a family physician, mean number per patient + s.d. 6.7 ± 7.9 7.2 ± 8.2
Visits to a family physician for asthma, mean number per 0.8 ± 1.3 1.0 ± 1.7patient ± s.d.
Prescriptions dispensed in the year preceding cohort
entry
lnhaled corticosteroids*
%users 51.5
mean number cf filled prescriptions per patient ± sU. 1.4 ± 2.2
Short-acting 32agonists*
¾ users 58.8
mean number cf filled prescriptions per patient ± s.d. 2.7 ± 4.0
Oral corticosteroids*
% users 18.9
mean number cf filled prescriptions per patient ± sU. 0.3 ± 0.8
Theophyllin, % users 1.8 3.2
Anti-leukotriene, % users 5.0 4.5
Daiiy dose calculated on the basis of fluticasone equivalent
* The distribution of these variables is identical in both groups since patients were matched on these variables
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Table 2. Crude and adjusted hazard ratios of treatment discontinuation comparing new users
0f combination (n=2559) and concurrent therapy (n2559).
Crude HR 95% CI Adjusted HR* 95% CI
Combination versus concurrent therapy 0.83 (0.79-0.88) 0.83 (0.78-0.88)
Socio-demographic characteristics
Age (5 years difference) 0.96 (0.95-0.98) 0.96 (0.94-0.97)
Male versus female 0.90 (0.85-0.95) 0.92 (0.86-0.98)
Social assistance (yes/no) 0.84 (0.79-0.89) 0.87 (0.82-0.93)
Living in rural versus urban area 0.98 (0.91-1.04) 0.94 (0.87-1 .00)
Initial prescription of combination or
concurrent therapy
Daily dose of inhaled corticosteroid
(fluticasone equivalent) prescribed, mcg
250 Reference Reference
>250—500 0.85 (0.74-0.98) 1.00 (0.87-1.16)
>500 1.34 (1.16-1.54) 1.60 (1.39-1.84)
Specialty of the prescribing physician
General practitioner Reference Reference
Respiratory physician 0.78 (0.72-0.86) 0.78 (0.70-0.86)
Other speciaiist 0.92 (0.83-1.03) 0.87 (0.78-0.97)
Prescriptions fihled
in the year preceding cohort entry
lnhaled corticosteroids (each additional 0 9Q (0 89-0 92
prescription) 0.85 (0.84-0.87)
Corticosteroids (each additional prescription) 0.96 (0.92-0.99) 1.00 (0.97-1 .04)
Short-acting 2-agonists (each additional 0 96 (0 95-0 96)
prescription) 0.92 (0.91-0.93) .
Anti-leukotriene (yes/no) 0.71 (0.62-0.82) 0.85 (0.73-0.98)
Theophylline (yes/no) 0.71 (0.59-0.85) 0.98 (0.81-1.18)
Number of different medications (each 0 993 0 987-0 999
additional prescription) 0.976 (0.97-0.981) .
Health care services for asthma
in the year prior to cohort entry (yeslno)
Hospitalization 0.94 (0.80-1.11) 1.06 (0.88-1.27)
Visit to an emergency department 0.82 (0.76-0.89) 0.85 (0.77-0.93)
Medical visit to a respiratory physician 0.85(0.78-0.93) 0.95 (0.86-1.06)
* Hazard ratios aUj usted for ail variables included in the table
Table 3. Treatment adherence for new users - combination or concurrent therapy.
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Combination
Number of patients followed for one 1368
year or more
Number of filled prescriptions per
patient during the first year of treatment
Mean ± s.d. 3.5 ± 3.4
Median 2
Range 1-21
Number of days on ptescribed
medications during the first year of
treatment
Mean ± s.d. 90.5 ± 90.7
Range
Treatment adherence to the prescribed
therapy while persistent
Number of patients with 2 filled
prescriptions
Percentage of days with the
prescribed dose
Mean ± s.d.
*p.value comparing combination and concurrent users < 0.003
¶J p-value < 0.05 comparing the use of LABA and ICS
** p-value 0.1238 comparing the use of LABA and ICS
Concurrent
ICS and LABA LABA ICS
1739 1739 1739
2.7 ± 2.6* 3.37 ± 3.20 3.47 ± 3.0811
2 1 1
1-14 1-19 1-21
73.1± 733* 89.8 ± 87.0 100.9 ± 87.911
Median 50 40 55 60
7-393 1 -448 4-433 5-51 1
879 685 859 913
55 ± 19
Median 53 55 50 50
Range
58 ± 21* 55 ± 19 53 ± 1 9**
4-100 14-100 3-100 3-100
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DISCUSSION
Brief summary of resuits
Patients on a combination therapy were found to be slightly more persistent than
patients treated with concurrent ICS and LABA from two different inhalers. Persistence
with combinations feu to 10% 12 months after initiation and declined to 5% over 2 years.
In the concurrent group, persistence decreased from 5% at 12 months to below 2% after
2 years. The Cox regression model showed that users of a combination therapy were
17% Iess Iikely to stop their treatment than users of a concurrent therapy. Adherence
during treatment persistence was also found to be Iow for both regimens: users of
combination and concurrent therapy took on average 55% and 58% of the prescribed
doses, respectively. This resuit is slightly higher than in the pubflshed literature where
compliance with inhaled medication is reported to be often Iess than 50%.140160167168
ComparabilitylConsistency with similar studies
Our findings are aiso consistent with two retrospective cohort studies2526 in which
adherence to treatment was measured in patients aged 12 years and over on the basis
of the number of prescriptions recorded in a United States daims database during a 12-
month period. Stoloif et al. were the first to observe that patients who were prescribed
LABNICS in combination obtained significantly more refuIs (4.06) compared with
patients prescribed fluticasone and salmeterol concurrently (2.35). Their study included
a smaller number of patients (2511 patients) in a wider range of age groups than in
ours. Stili, the outcome in terms of persistence with combined inhalers was in the same
direction as ours, but the observed difference was larger. Stempel et al. similarly
identified a cohort (n=3503) on the basis of the index medication, with unequal num bers
of patients between groups. The mean number of prescription refuis for ICS/LABA
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combination (3.98) was significantly higher than ICS (2.29) and the ICS component of
ICS/LABA (2.36) and ICS/anti-Ieukotrienes (2.15). The mean number of treatment days
was greater for combinations compared to ICS, ICS/LABA concurrently, and ICS/anti
leukotrienes. One major methodological difference between those two studies and ours
is that their patients were flot newly treated with a combination or a concurrent therapy
at the beginning of the study. At the beginning of the 12-month observation period,
patients on concurrent therapy in these two studies might have been treated for a longer
period 0f time than patients on combination therapy considering that long-acting f32-
agonists arrived on the market a few years befote the combination therapy. Since
patients might have been treated with combination or concurrent therapy for different
lengths of time at the beginning ofthe 12-month observation period, they may therefore
not be comparable in terms of the likelihood to be persistent or adherent to their therapy
considering that persistence and adherence are known to vary considerably over
time.63169’17° A tendency for persistence to decrease over time was also observed in our
study. This phenomenon might explain why in the Stoloif et al. and in the Stempel et al.
studies, patients on combination therapy were found to be more adherent while patients
in the concurrent group were found to be less adherent than in our study, leading to a
larger difference between the two treatment groups.
Predictors of Persistence
In our study, through the Cox regression model, we also found that older
patients, men, patients receiving social assistance and patients taking a larger number
0f different medications were less likely to discontinue their treatment. Markers of
uncontrolled and severe asthma such as the average dose of ICS at cohort entry; at
least one visit to an emergency department for asthma or to asthma specialists; as well
as asthma drug utilization in the year prior to the entry in the cohort, were found to be
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significant predictors of higher persistence ta the asthma treatments under study. This
finding suggests that patients with more severe asthma may tend ta be more persistent
on their controller medication. However, patients with a dosage higher than 500 mcg of
ICS in fluticasone equivalent at cohort entry were found ta be significantly more likely ta
discontinue their treatment. This may be because more inhalations need ta be
performed every time patients need to reach that dose, and this additional complexity in
taking their medications may be perceived as a burden for some patients and eventually
drive them to cease their treatment. In our study, we found that 10% of combination
users were stili persistent one year after the initiation of therapy, while this percentage
was slightly below 5% for concurrent users. The carresponding figures at twa years for
each regimen were 5% and below 2% respectively, showing that treatment simplification
with the single inhaler may have some impact on the rate of persistence. When
assessing the persistence on ICS and on LABA medications separately, rates yield
slightly better persistence for ICS as compared with LABA (p-value for log-rank test <
0.0001). One year after the initiation of the concurrent therapy, approximately 11% of
the patients were stili using their LABA and 13% were stiit using their ICS. Over time
the persistence rate converged as these figures were close ta 5% after twa years, a rate
that is similar ta what we found for combination users. Overail, the relevance of these
resuits from a clinical standpoint is of considerable magnitude considering that each
25% increase in the proportion of time without ICS medication resuits in doubling of the
rate of asthma-related hospitalizations.124
Biaises - Confounding
In a recent database study, it was found that the addition of salmeterol as an
additional controller was associated with a significant decrease in inhaled
corticosteroid use, suggesting decreased adherence in patients on the concomitant
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regimen.14° Although, as shown by this study, it can be expected that the reduced
complexity of using one inhaler instead of two could be easier to manage for patients, it
is worthy as in any observational study, to review the biases that might have distorted
the magnitude of our resuits. Biases are systematic errors that lead to an incorrect
estimate 0f effect or association; several factors could bias the study resuits such that
they would cancel out, reduce or amplify the real effect. it is important to recognize
those variables that are not part of the real association between exposure and disease,
that predict the disease, and that are unequally distributed between exposure groups,
because they couid confound our thinking about the relationship between drug regimen
and treatment persistence. For example, studies have shown that asthma is more
prevalent in urban areas than in less polluted areas,171 and worldwide asthma
prevalence is expected to increase further, due in part to growing urbanization and
pollution.29 Asthma is indeed more prevalent in urban regions, yet living in the city is
flot really the cause of asthma. The prevalence of asthma is also apparently higher in
lower social classes172173. In our study, the place of residence (rural/urban) and the
social assistance beneficiary status were assessed in the patient’s socio-demographic
characteristics of our study groups and also included in the Cox regression model, but
found to be similar in both treatment groups. Moreover, the place of residence may be
associated with higher asthma prevalence, but in our study, ail the patients were
already asthmatics. Living in an urban environment could be a confounder in our study
if found to be a determinant of persistence and if the percentage of urban inhabitants
differed between our treatment groups. In our Cox regression model, the place cf
residence was not found to be a strong predictor of persistence to asthma treatment
(adjusted hazard ratio= 0.94; 95%Cl: 0.88-1.00).
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Indication bias and adjustment for asthma control and severity
Dur study adjusted for patients’ characteristics between groups to aise account
for a potential bias by indication, whereby characteristics (age, for instance) that have
Ied the physician to choose certain drug may be important determinants cf persistence
in addition te the characteristics of the drug itself.
One may speculate that sicker patients might be more likely te perceive a benefit
from their asthma controller therapy and thus, more Iikely te be persistent.
Consequently, and with respect te our study, ail efforts were made te control for these
differences between treatment groups by matching patients one-to-one on the basis of
the number of filled prescriptions of short-acting 32-agonists, ICS, and oral
corticosteroids in the year prier to cohort entry, and on the prescribed dose cf ICS at
cohort entry, ail cf which are well known markers cf disease severity and contrcl.62’174”75
Physicians may be inclined to prescribe certain types of medication depending on the
level cf asthma control or severity. A potential bias frcm our study ccnsists cf
confounding induced by the lack cf random allocation cf patients to treatment with the
ccntrcllers under study. Such bias is expected as patients with more severe asthma are
more likely to be prescribed and dispensed the existing concurrent treatment. Adjusting
for asthma control and severity mitigates for this potential bias by indication. Dur study
was therefore designed te avcid this bias by matching patients in both groups with
respect te markers of asthma severity and control. Despite such tight matching, the
concurrent stiil appeared te have slight!y more severe asthma than the combinatien
therapy patients. In order te control for this residual confounding by adjusting for these
differences that may still exist between the twc treatment grcups, even after matching
accerding te asthma severity and centrol, we performed a regressien analysis including
variables such as asthma-related ED visits and hospitalizations.
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Moreovec, we cannot completely cule out the possibility of residual confounding
in the association between treatment regimen and persistence rate; variables would
undoubtedly have to be known or measurable in order to be controlled. Therefore,
some confounding by indication may remain. Despite matching, the fact that concurrent
users appeared to be slightly more severe than combination users at cohort entry, is
likely to under estimate the true difference in persistence. Therefore, our study results
could be considered as conservative given that the higher level of severity and lack of
control seen in the concurrent group — based on higher frequency of asthma-related ED
visits and hospitalizations prior to cohort entry and on the higher number of different
medications at cohort entry — is likely to minimize the difference in persistence observed
between the two groups..
In our study, drug exposure is assessed by the dispensing of a prescription
within a specified time period, prior to the outcome of interest: refill or discontinuation176.
The drug supply for the most recent filI is used to determine whether the renewal of the
prescription occurred within a specified grace period. Although cumulative dosage and
duration of drug exposure may not be precisely determined with the refill information,
the persistence provides an estimate of the duration of treatment. However, in our study
we per[ormed sensitivity analyses with Kaplan-Meier estimates and found that the
relationship between the curves indicating persistence for each group were not
influenced by the choice of the grace period duration for treatment renewal; differences
of similar magnitude in the persistence rate could still be observed between groups,
regardless of the grace period.
One argument that is often put forward in fayot of using a combination therapy
instead of ICS and LABA in sepatate inhalers is that patients might be more likely to
stop their ICS and continue their LABA since they might perceive more easily the benefit
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cf the LABA. It is important to re-emphasize that the use cf LABA without ICS is flot a
recommended therapeutic option in Canada, and may resuit in safety issues, including
higher risk cf morbidity and mortality.177 Our study findings showed the opposite:
patients who started a concurrent therapy were slightly more Iikely to stop LABA than
ICS.
Selection
Persistence on LABNICS therapy is essential to prevent exacerbations in
patients suffering from persistent asthma. Based on the combination or concurrent
LABNICS regimens indicated for asthma at the time of the study, we assumed that
patients treated with those regimens were treated for asthma because there is no
information available in the database on the clinical indication for a drug prescription.
The diagnosis registered in the database was assumed to be correct for the purpose cf
our study although it was net confirmed with medical charts. However, a subsequent
study recently confirmed that diagnoses recorded in the Medical Services database cf
Quebec are valid te identify patients with asthma.178
Nevertheless, given the Iikelihcod that LABNICS could possibly have been
prescribed in the treatment of other conditions; for example, chronic obstructive
pulmonary disease (COPD), it was important that cur study exciudes those COPD
patients and considers only patients suffering from asthma. To minimize this issue,
patients included in our study had to be Iess than 45 years cld at cohort entry.
Another important inclusion criteria in our study to minimize the between-group
differences in severity for the evaluaticn cf persistence and adherence was that patients
needed te be exempt from having any recorded prescription cf the regimens under
study in the year prier te their entry in the cohort. The objective cf this selection criteria
C
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was te ensure that the selected patients were really n
ew users, beginning either
combination or concurrent LABNICS therapy at the time
cf inclusion in the cehort. Yet,
there is still a potential for off-label prescription, as has l
ikely occurred in Quebec with
these ICS/LABA cembination inhalers becoming a panacea
for patients with symptoms
cf cough, dyspnea, or chest tightness.82 This phenomen
on might distort the resuit by
increasing the rate cf discentinuation since these patients w
ould not necessarily be non-
persistent if they were actually prescribed the medication
for acute utilization. In our
study this was net the case as the majerity cf patients were apparently
found te be
mederate te severe asthmatics as indicated in Table 1 cf t
he article.
Source data — Administrative database studies
Administrative health-care daims databases offer a nu
mber cf attractive features
from which te form the evidence-base for conducting
pharmacoecoepidemiologic
studies; these features include the ready availability o
f data, real-world health-care
practice patterns, potentially large sample sizes, and lo
nger follow-up periods.179 In
Canada, the RAMQ and the Saskatchewan Health databases ar
e widely used for
pharmacoepidemiologic research. In the US, administ
rative databases from different
health maintenance or managed care organization (Medicaid, for exa
mple) are used for
the same purpese. In the UK, the General Research
Practice Database (GPRD) has
resulted in over 400 clinical reviews and papers180.
In addition, administrative
databases have been used specifically in asthma te addre
ss the issue cf consistency in
resuits from basic science, clinical trials, and observational
experience, more specifically
te validate observations from clinical trials, confirming that
initial treatment with ICS and
combined ICS/LABA treatment are the mest effective
stepwise appreaches te the
treatment of asthma.181
C
Some prescription daims databases may not contain ail the required data to
perform a prescription refui analysis. However, the accuracy, quality and
comprehensiveness of the drug information contained in the provincial prescription
daims database in Quebec (RAMQ) used for our study was assessed, analyzed and
validated specifically so that it may be used to monitor drug exposure and physician
prescribing. In the published validation study of the RAMQ database, it was concluded
that the prescription daims database in Québec may represent one of the most accurate
means of determining drugs dispensed to individuals.158
Prescriptïon analyses compared to other measures
Previous compliance research in the field of asthma - assessing whether patients
are taking their medication as prescribed - was based on different techniques, inciuding
blood-level monitoring (biochemical measures of theophylline), patient diaries (self
reported), physician opinion, measuring of the amount of drug used (weighing
canisters), or electronic-device measures like a Turbuhaler Inhalation Computer or
Nebulizer Chronolog.140’82’83 lt has been reported that self reports, patient diaries, and
physician opinion tend to overestimate compliance.167183’184 In itself, eliminating the
potential of recall bias for drug consumption constitutes a considerable advantage of
using an administrative database to measure drug exposure185. In epidemiology, the
recall bias us categorized as an observation bias whereby individuals may under-report
their conditions or over-report utilization behaviors during questionnaire-based studies.
In our study, we were able to foliow patients for a duration of up to three years. In other
types 0f study designs, losses to follow-up may occur as patients become too iii and
interrupt their participation, whïle healthier individuals remain in the study, hence
skewing the results.
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Compliance measures using canister weight can be distorted by epis
odes of
canister dumping, or expeliing medication into the air before evaluation, as
evidenced in
the study by Rand et ai.182 A study by Braunstein et al.183 measuring com
pliance report,
physician rating, and canister weight, ail gave significantly higher estimat
es of patient
compliance than the Nebulizer Chronolog electronic method. Finally,
assessing
adherence through medical charts also has limitations since these may not
aiways be
complete in terms of information on prescribed medication, and prescri
bing behavior
may vary due to the particularity of medical practice by physician
s participating to
research studies. The currently available electronic measure devic
es offer the most
accurate and valid measurement of patient compliance140182183186, but t
hat technology
has been used only in a few studies.
Benefits of using an admïnïstrative database in our study
This study was designed and conducted to provide significant
real-life
information for asthma patients and their treating physicians in terms of ad
herence and
persistence, which would stem from the reduced complexity offered by
combination
therapy regimens. Overail, these resuits help inform clinical pr
actice about the
utilization patterns of combination therapy, and highlight the unmet me
dical need in
terms of persistence and adherence on controller asthma medication. On
that basis, the
main strength of this study is that our analyses were performed on a larg
e population
based administrative database, with a large sample size, providing high st
atistical power
to the analyses as well as population-based information that is highly
representative of
the real-life drug utilization for treating asthma in ciinical practice.
ç
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Limitations of our study
One limitation of this study, inherent to da
ims database analyses, is the absence
of clinical markers of asthma severity and
control such as pulmonary function tests
and
symptoms scores. However, in our study
, extremely useful markers of disease s
everity
and control allowed us to match and a
djust for the potential confounding effects of
asthma severity and control. Accordin
g to the Canadian Consensus2 guid
elines,
disease severity must be evaluated p
rior to treatment initiation and monit
ored
subsequently through regular follow-up
visits once patients are under treatm
ent.
Assessing the dose of inhaled corticost
eroids needed to provide control of sym
ptoms
may also be an indicator of severity, ex
cept in patients with very severe asth
ma who
cannot be controlled with corticosteroids.
The level of asthma control achieved b
y a
patient is acknowledged to be a key clin
ical outcome measure in asthma mana
gement,
and should also be assessed regularly o
nce the patient is already under treatme
nt. In
pharmacy databases such as the RAMQ, the qua
ntity of medication dispensed by the
pharmacist has been used to impute a dai
ly dose; drug refuIs are used as a pro
xy for
drug consumption, which in turn appro
ximates asthma severity and control.
In our
study, surrogate markers for both asthm
a severity and asthma conttol were us
ed to
define the study group at the one-to-on
e matching stage. Our surrogate mark
ers of
asthma severity consisted of the number
of prescriptions of ICS filled in the
year
preceding cohort entry and the daily dose o
f ICS prescribed at cohort entry. We
also
assessed the number of prescriptions o
f oral corticosteroids and short-acting 132-
agonists as surrogate markers of asthma
control. These markers were also incl
uded in
our adjusted Cox regression model, along with
patients socio-demographic
characteristics as welI as health care re
source utilization, such as ED visi
ts and
hospitalisations for asthma.
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In addition, because the study was based en
tirely on computerized data of dispensed
medications to estimate physician prescrib
ing, the actual prescribing could be
underestimated because not aH prescriptions wri
tten for patient use are presented to the
pharmacy187 and the medicine supplied to the
patient through pharmaceutical samples
are not recorded either. Furthermore, dispensed
prescriptions may not coincide exactly
with the actual intake of medications (dose-timing, taking
the medication within the
prescribed time frame); patients may request refllls regula
rly, even if they have not run
out of drug, whereas others may stockpile me
dications or hold quantities of medications
for their convenience188. This could potential
ly result in some misclassification of drug
use185 which, if present, might to some exten
t dilute the association between drug
regimen and persistence. It is assumed by
design that treatment gaps are due to
noncompliance by the patient rather than drug
discontinuation by the clinician. The use
of administrative pharmacy daims data to analy
ze adherence and persistence is limited
in that without additional clinica) data from medical recor
ds, we are unable to determine
either the medical reason for the start of a new
asthma controller or the reason for non
adherence or non-persistence to the therapy.16
1
Linking a daims data analysis to medical reco
rds could further strengthen the
study by providing indications on worsening fa
ctors such as smoking, exercising heavily,
cold temperature and perhaps the level of allerg
ens in each patient’s environment. The
source database used in our study had prev
iously been validated158 to mitigate the
potential of inaccurate data recording and u
sed in similar peer-reviewed published
research studies.18919° This also ensures that the
target population of patients starting a
new treatment could accurately be identified in
the database.
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Study relevance and future research topics
Our results demonstrate that persistence and adhere
nce on LABNICS controller
therapies presently used in the prophylaxis of asthm
a remains very poor among adult
asthmatic patients. The implication of our resu
lts for the treatment of asthma is
important and this finding may even curtail the conc
lusions from the Stempel et al. and
Stoloif et al. studies.2526 The latter was publishe
d eariier and recognized as the first
substantive evidence that the use of (CS/LABA therapy in
a combination inhaler
improves compliance, and that this may contribu
te to the improved asthma control
obtained with combination thetapy in general practic
e91 Dur results appear to be more
in line with previous suggestions that complian
ce with inhalers dramatically diminish
over time on treatment suggesting that long-t
erm compliance or persistence to
prescribed thetapy is hard to attain.192 It has bee
n shown that non-compliance in
asthma might contribute to its morbidity.193 Clear
ly, our study showed that many
patients still take their controller medication spora
dicaliy (even with the single-inhaler
combination regimen) and we should question the impact of this
phenomenon in relation
to a patient’s health, as well as on the use and cos
t of health care services. Although
previous research had shown that simpler, less freq
uent dosing regimens resulted in
better compliance across a variety of therapeutic c
lasses15, further research involving
structured electronic monitoring of inhalers combined
with pulmonary function measures
may help elucidating the implications of the obser
ved irregular use and discontinuation
of combination drugs. Such measurements would
clarify the question if it accurately
measured the magnitude of compliance improvem
ent and related benefits in terms of
asthma outcomes. It is howevet reasonable to assu
me that sporadic asthma controller
utilization behaviors may resuit in suboptimal clinical
outcomes as evaluated in a real
life setting (effectiveness) and associated opportunity losses in
terms of quality of life
C
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and productivity. Stili, additional research is neede
d te estimate the impact cf sub
optimal use cf controller therapy on asthma morbidity a
nd use cf health cate services.
Moreover, additional research linking patients’ behavi
oral patterns te petsistence and
adherence might assist physicians in optimizing the
asthma management cf their
patients. Amongst the strategies to ensure that the
potential benefits suggested by
clinical trials and observational studies can be translate
d into benefits at the clinical and
population 1evel192, a stronget emphasis on the importan
ce of regular treatment through
patient education or interventions involving the assi
stance cf pharmacistsl7C might be
considered.
C
CONCLUSION
Overail, combination therapy patients were found to be s
lightly more persistent
than patients treated with ICS and LABA taken in two d
ifferent inhalers. Adherence to
the prescribed regimen during treatment persistence w
as siighUy bwer among users 0f
combination than concurrent therapy. According to the
resuits cf our study, there is stiil
very Iow persistence to inhaled controBer therapies a
mong aduft asthmatic patients.
This finding is important in that it reinfotces the impor
tance of addressing the issue cf
asthma management beyond merely reducing the c
omplexity of drug regimens or
administration. It suggests that patients are Iess Iik
ely to benefit from the clinically
proven efficacy of drugs due to non-persistence and
non-adherence, however further
research is needed to assess whether this differen
ce in persistence in favor cf
combination therapy Ieads to better clinical outcome and e
ffectiveness.
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Table I RAMQ antï-asthmatic medications lïst wïth drug code
s
Common Coding Drug Name
364 aminophylline
780 beclomethasone (dipropionate)
Inhaled only
45499 budesonide
lnhaled only
39419 ctomoglicate_sodique
3380 epinephrine (bitartrate)
3406 epinephrine_(chlorhydrate)
3419 epinephrine racemique (chlorhydrate)
38548 fenoterol (bromhydrate)
38730 flunisolide
lnhaled only
47050 fluticasone (propionate
lnhaled only
47231 formoterol (fumarate)
47271 formoterol (fumarate dihydrate)
43124 ipratropium (bromure)
47186 ipratropium (bromure)? salbutamol (sulfa
te)
5083 isoproterenol (chlorhydrate)
5096 isoproterenol (chlorhydrate)/ phenylephr
ine (bitartrate)
5109 isoproterenol (chlorhydrate)/ phenylephr
ine (chlorhydrate)
5070 isoproterenol (sulfate)
45555 ketotifene (fumarate)
47303 montelukast sodium
47033 nedocromil sodium
6721 orciprenaline (sulfate)
43475 oxtriphylline
47153 pirbuterol (acetate)
45547 procaterol hemihydrate (chlorhydrate)
10530 salbutamol
33634 salbutamol (sulfate)
47335 salmeterol (xinafoate) I fluticasone (prop
ionate)
47112 salmeterol_(xinafoate)
34180 terbutaline_(sulfate)
9464 theophylline
9490 theophylline (aminoacetate calcium)
9737 triamcinolone (acetonide)
lnhaled only
47266 zafirlukast
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Table 2. Canadian Consensus: Asthma Control Cr
iterïa
Daytime symptoms less than fout days per week
Nightime symptoms less than one night per week
Normal physical activity
Mild, infrequent exacerbations
No absenteeism due to asthma
Fewer than fout doses per week of a fast-acting beta2
-agonist needed*
Forced expiratory volume in 1 second or peak expira
tory flow at 90% of
their personal best or greater
Diurnal variability in peak expiratory flow of less tha
n 10% to 15%
Source: Can Respir J Vol 1 1 Suppl A May/June
20042
Table 3. Canadian Consensus: Therapies currently
used in asthma
Bronchodilators Anti-infl
ammatory therapies
lnhaled short-acting 32-agonists: l
nhaled corticosteroids:
salbutamol, terbutaline, and fenoterol b
udesonide, fluticasone proprionate,
beclomethasone dipropionate
I nhaled long-acting 32-agonists: A
ntileukotrienes:
salmeterol and formoterol
montelukast and zafirlucast
Inhaled anticholinergics: Cromo
nes:
ipratropium bromide and tiotropium disodiu
m cromoglycate and nedocromil
bromide sodium
Theophylline: Anti-im
munoglobulin E: omalizumab
slow-release theophylline and
aminophylline
Data adapted from Canadian Consensus.
Source: Can Respir J Vol 11 Suppl A MaytJ une
20042
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Table 4. Canadïan Consensus: Classifïcation of Asthma S
everïty
Severity Symptoms Treatment
Short-acting beta-agonist use
Ve severe
May be controUed or High doses of inhaled co
rticosteroids
ry flot well controlled Additional therapy
Oral corticosteroids
Short-acting beta-agonist use
Severe WeB controBed High dos
es of inhaled corUcosteroids
Additional therapy
Short-acting beta-agonist use
Moderate WeB controlled Low
-to-moderate doses of inhaled corticosteroids
± Additional therapy
MilU Well controlled
Short-acting beta-agonist use occasionally
Low doses of inhaled corticosteroids
.
Short-acting beta-agonist use rarely
Very mild Mild-infrequent
Source: Canadian Asthma Consensus Report, CMA
J 199927
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Table 5. Asthma lnterventïons and Adherence
Outcome*
Intervention Control
Adherence outcome
Pamphlet, workbook, counseling, Severity of as
thma 10-item checklist for
telephone, follow-up, support group symptoms
inhaler use
‘
Bothered by asthma Self-Report scales
Respiratory problems Subjective health care
Impact on life scales
• Asthma education program , Written Misse
d work Weight of used canister
self-management action plan, Hospitaliz
ation
W Symptom monitoring ED vis itsSteroid Use
o’
Patient brochure, 2 group sessions Forced expira
tory Percentage dispensed
(2h) volume in 1 s
divided by prescribed
1 or 2 individual sessions (40 mm) Peak expiratory flow
from both a nurse and a
W physiotherapist, individual treatment
plan on the basis of the acquired
‘ ,
personal information and 2 week of
peak flow monitoring
(!3T-
Asthma consultation (1 h) with study Peak flow
Adherence to self
.
nurse, followed up by > 2 Symptoms
scores management or
,
consultations (30 mm) at 6 week Severe attacks
moderate attacks
intervals Days off w
ork Adherence to self
Use of medical management of severe
—I services attac
ks
Discussion of asthma management Force expi
ratory Self-report
zone systems with pediatricians volume in 1 s
Physician estimate
4 individual sessions with asthma Symptoms s
everity
W nurse
Hospital admissions
3 educational group sessions with Oral steroids
> asthma nurse
* Adapted from MacDonald H. et al.42
Ç
Figure 1. Continuum of treatments for asthma manag
ement
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Continuum of asthma management. Very mild
asthma is treated
with short-acting betaagonists, taken as needed.
inhaied coflicosteroïds (ICSs)
may be introduced as the initial maintenanc
e treatment for asthma, even in
subjects who report asthma symptoms iess than three tim
es per week. For
patients who cannot or wil flot use ICSs, leuko
triene receptor antagonist are an
alternative, although they are less effective than
low doses of ICSs. If asthma is
flot adequately controlled by 10w doses of 1CS
s, additional therapy should be
considered. Addition of long-acting beta2-agonis
t should be considered as the
first option. As an alternative, addition of leu
kotriene receptor antagonitst or
increasing ICSs to a moderate dose may be co
nsidered. Theophylline may be
considered as a third therapeutic option. Seve
re asthma may require additional
treatment with prednisone. Asthma contrai should
be assessed at each visit, and
maintenance therapy should be altered if
necessary. Any alteration in
medication therapy should be considered a trial, a
nd effectiveness should be te
evaluated after a reasonable period of time.
After achieving full control, the
medication shouid be reduced to the minimum n
ecessary to maintain control.
Regularly assess:
Ccqifr:.I
Irigqer
Complicmce
—
Inhd.r technique
Cc.-morbidity
ikL1
Mci-on therapy
Low
Inhaleci corticosteroids
Mod e rate
F..
H igh
EnvronmentdccntrnI’’
Education, Wriften action plan and FUlow-up
QDclercte .vccIer:iteIy Severe
rnild
Source: Can Respir J Vol 11 Suppl A May/J une
20042
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